Method for stabilizing binding of nk cell and antibody, and use thereof

HK40083556BActive Publication Date: 2026-08-28GAIA BIOMEDICINE INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
HK62023071804
Authority / Receiving Office
HK · HK
Patent Type
Patents
Current Assignee / Owner
Priority Date
2020-06-30
Filing Date
2023-04-21
Publication Date
2026-08-28

AI Technical Summary

Technical Problem

In existing technologies, antibody drugs cannot effectively distinguish between tumor cells and normal cells, resulting in non-tumor-targeted toxic effects. NK cells cannot stably bind to antibodies, leading to the killing of normal cells.

Method used

By preparing fusion proteins that can bind to NK cell surface proteins (region I) and antibodies (region II), the binding of NK cells to antibodies can be stably maintained. Stable binding is achieved by utilizing surface proteins such as NKp46, NKp30, and NKG2D and antibody-binding fragments (scFv).

Benefits of technology

This approach enables NK cells to specifically utilize antibody drugs, reducing the killing of normal cells by macrophage-based immune cells and improving the targeting and safety of antibody drugs.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000000_0000_ABST
    Figure 00000000_0000_ABST
Patent Text Reader

Abstract

The present application relates to a method for stabilizing the binding of an antibody to an NK cell. The method comprises the use of a substance having a region I capable of binding to a surface protein of an NK cell and a region II capable of binding to an antibody. The substance comprises region I and region II, and can further comprise a linker moiety.
Need to check novelty before this filing date? Find Prior Art

Description

TECHNICAL FIELD

[0001] The present application relates to a method for stabilizing the binding of NK cells to antibodies. The present application is useful in the field of immunotherapy of cancer using NK cells, production of regenerative medicine products for the same, and the like. BACKGROUND

[0002] Antibody drugs are designed to show an anti-tumor effect by specifically binding to tumor cells expressing a specific antigen on the cell surface, and exerting antibody-dependent cellular cytotoxicity (ADCC) activity. However, it is known that as long as the antigen targeted is expressed, it will also bind to normal cells and exert the same toxic activity (non-tumor targeted toxic effect). That is, the antibody drug itself cannot determine whether the cell is a tumor or not. Moreover, this phenomenon is confirmed even in the absence of complement if leukocytes are present, and thus it is shown that if an immune cell binds to an antibody, it can also kill normal cells through ADCC activity. For example, it is known that by administering rituximab (Rituxan) targeting CD20 expressed by B cells, as a side effect, normal B cells are killed. So far, no method for avoiding this non-tumor targeted toxic effect has been known, and it has become one of the biggest problems faced by CAR-T cells as the latest immune cell therapy. It has been confirmed through various aspects that the normal cells killed by binding to antibodies are mainly cells of the macrophage lineage (non-patent literature 1).

[0003] On the other hand, natural killer cells (NK cells) are cytotoxic lymphocytes that play a role as a major factor of natural immunity, and are important in the rejection of tumor cells or virus-infected cells. NK cell-based cancer immunotherapy in which NK cells expanded and activated in vitro are administered to patients is attracting attention as a treatment method with fewer side effects. The present inventors and others have developed a new cell of NK-like cells with high cytotoxic activity, and have obtained a unique idea of administering an antibody drug to a patient after binding to such a cell in vitro (patent literature 1).

[0004] On the other hand, a multispecific binding protein that can bind to a surface protein of an NK cell is proposed. For example, Patent Literature 2 proposes a chimeric fusion molecule for guiding an NK cell to an antigen cell, having a tumor antigen binding domain and an immune cell binding domain, the antigen binding domain comprising an isolated antibody or fragment of the antigen binding domain, the isolated antibody comprising an immunoglobulin variable region and a constant region, and the immune cell binding being a ligand specific to an NK cell receptor. In addition, Patent Literature 3 proposes a scheme in which an NKp46 binding immunoglobulin region and a protein comprising the variable region, such as an antibody and a multispecific protein, are used to specifically redirect an NK cell to lyse a target cell of interest. Further, in Patent Literature 4, a scheme is proposed in which an NKG2D receptor and a multispecific binding protein that binds to CD16 are bound to an NK cell to activate the NK cell, and the multispecific binding protein can comprise an amino acid sequence that is at least 90% identical to amino acids 234 to 332 of a human IgG1 antibody.

[0005] Prior Art Documents

[0006] Patent Literature

[0007] Patent Literature 1: Japanese Patent Application Laid-Open No. 2018-193303

[0008] Patent Literature 2: Japanese Patent Application Laid-Open No. 2009-500346

[0009] Patent Literature 3: International Publication No. 2017 / 114694 (Japanese Patent Application Laid-Open No. 2019-503713)

[0010] Patent Literature 4: Japanese Patent Application Laid-Open No. 2020-506971

[0011] Non-Patent Literature

[0012] Non-Patent Literature 1: Uchida J, et al. J Exp Med. 2004, Sugata K, et al, Sci Rep. 2016 SUMMARY

[0013] Problems to be Solved by the Invention

[0014] Macrophage lineage cells cannot distinguish between tumor cells and normal cells, whereas NK cells can discriminate between tumor cells and normal cells. Therefore, if a condition in which NK cells become the only effector of the ADCC activity of an antibody drug can be created, theoretically, non-tumor targeting toxicity (on-target off-tumor) effects can be completely eliminated.

[0015] In order to produce a condition in which NK cells are the only effectors of ADCC activity, it is unrealistic to exclude cells of the macrophage system throughout the body, and in view of this, it is desirable to avoid administration of an antibody drug itself systemically by drip or the like, and to administer in a state in which the antibody drug is bound to NK cells.

[0016] However, according to the research by the present inventors et al., it was found that even if an antibody drug of interest is bound to NK cells, the antibody drug of interest is detached from the NK cells in the presence of a specific component or in the presence of other antibodies. Therefore, a technology capable of stably fixing an antibody to NK cells is required.

[0017] Means for solving the problem

[0018] This time, the present inventors et al. prepared a fusion protein composed of region I capable of binding to a surface protein of an NK cell and region II capable of binding to an antibody, and a linker portion connecting region I and region II, found that binding of NK cells to an antibody can be stably maintained by this, and thus completed the present invention.

[0019] The present invention provides the following.

[0020] [1] A method of stably binding an NK cell to an antibody, which uses a substance having:

[0021] region I capable of binding to a surface protein of an NK cell; and

[0022] region II capable of binding to an antibody.

[0023] [2] The method according to 1, wherein the surface protein of the NK cell is any one selected from the group consisting of NKp46, NKp30, NKG2D, IL-15R, IL-2R, KIR3DS1, NKG2C, NKp80, NKp65, NKp44, LALRA1, LILRA2, DNAM-1, and 2B4.

[0024] [3] The method according to 1 or 2, wherein at least one of region I and region II is a single-chain Fv fragment (scFv).

[0025] [4] The method according to any one of 1 to 3, wherein the antibody is an antibody drug for treating cancer or an infectious disease.

[0026] [5] A method of preparing an NK cell population, comprising the following steps:

[0027] (1) preparing an NK cell population, an antibody, and a substance having region I capable of binding to a surface protein of an NK cell and region II capable of binding to an antibody;

[0028] (2) In the presence of protein, an antibody is added to the NK cell population to obtain an NK cell population that binds to the antibody; at this time, the NK cells bind to region I of the substance, and the antibody binds to region II of the substance, and the substance stabilizes the binding of NK cells and antibodies.

[0029] [6] According to the preparation method described in 5, the antibody is an antibody drug used to treat cancer or infectious diseases.

[0030] [7] A pharmaceutical composition comprising a population of NK cells that bind to an antibody drug, wherein the binding of the antibody drug to the NK cells is stabilized by a substance having the following regions:

[0031] Region I, which can bind to the surface proteins of NK cells; and

[0032] Region II, which can bind to antibodies.

[0033] Invention Effects

[0034] According to the present invention, since the antibody drug is specifically targeted at NK cells, it is expected to suppress the side effect of killing normal cells bound to the antibody drug caused by macrophage-based immune cells.

[0035] Existing methods for enhancing antibody binding activity utilize alterations in the glycan structure of the Fc region of the antibody (low-fucose antibodies) or changes in the amino acid sequence, etc. However, this invention achieves stable antibody binding to NK cells through a completely different method. When anchoring antibodies to NK cells according to this invention, molecules with signals preferred for NK cell activation and survival can be selected as the surface proteins of the anchored NK cells.

[0036] Brief description of the attached diagram

[0037] [ Figure 1 The killing effect of NK cells on Allo-WBCs when antibody drugs are used in combination.

[0038] [ Figure 2 Retention of antibody drugs by NK cells in culture medium.

[0039] [ Figure 3 The effect of culture medium additives on the binding of NK cells to antibody drugs.

[0040] [ Figure 4 The effect of blood components on the binding of NK cells to antibody drugs.

[0041] [ Figure 5 The effect of competitive IgG on the binding of NK cells to antibody drugs.

[0042] [ Figure 6The sequence used in the example. The lower case part is NKp46 sFv, the boxed part is Protein G, and the underlined part is a linker. In the base sequence, positions (1)..(57) are a 30K signal peptide-coding region, (58)..(222) and (298)..(432) are protein G-coding regions, (433)..(477) are a (G4S)3 linker-coding region, (478)..(1212) are a scFv (NKp46) coding region, (1213)..(1233) are a TEV protease-coding region, (1234)..(1251) and (1276)..(1293) are His tag-coding regions, and (1252)..(1275) are a Strep tag II-coding region.

[0043] [ Figure 7 ]Antibody drugs were anchored using the prototype substance. (1): high activity NK cells + PBS, (2): the prototype substance 350 μg / ml was added to the high activity NK cells, and after reacting for 1 hour at room temperature, Herceptin 1 μg / ml was added, and after reacting for 1 hour at room temperature, (3): the prototype substance 350 μg / ml was added to Herceptin 1 μg / ml, and after reacting for 1 hour at room temperature, high activity NK cells were added, and after reacting for 1 hour at room temperature.

[0044] [ Figure 8 ]The binding of cells to antibodies was stabilized by anchoring. High activity NK cells were suspended in PBS containing various antibody drugs in the presence or absence of the prototype substance, and after washing once with PBS, antibody staining was performed, and the presence or absence of binding of each antibody drug was determined. It was found that regardless of the antibody drug used, the binding of cells to antibodies was stabilized by anchoring using the prototype substance.

[0045] DETAILED DESCRIPTION OF THE INVENTION

[0046] The present application relates to a method for stabilizing the binding of NK cells to antibodies using a substance having the following regions.

[0047] Region I capable of binding to a surface protein of an NK cell; and

[0048] Region II capable of binding to an antibody.

[0049] [Region I, Region II]

[0050] Region I (a region capable of binding to a surface protein of an NK cell)

[0051] As the surface protein of an NK cell to which Region I of the substance of the present application binds, various protein molecules on the surface of an NK cell can be selected as long as the binding of an antibody to CD16 (FcyRIII) on an NK cell is not hindered. As examples of such proteins, NKp46, NKp30, NKG2D, IL-15R, IL-2R, KIR3DS1, NKG2C, NKp80, NKp65, NKp44, LALRA1, LILRA2, DNAM-1, and 2B4 can be given.

[0052] The not hindering the binding of an antibody to CD16 (FcyRIII) on an NK cell means that, for example, the steric structure (e.g., height) of the substance is appropriate when the substance binds to the cell surface protein and the antibody.

[0053] Among the above-mentioned NK cell surface proteins, as the surface protein of an NK cell to which Region I of the substance of the present application binds, a protein that is expected to have a signal preferable for the activation or survival of an NK cell by binding is preferable. As examples of this, NKp30, NKp46, NKG2D, and IL-15R can be given. One particularly preferable example is NKp46. NKp46 also has many ITAMs (immunoreceptor tyrosine-based activation motif) among the activating receptors possessed by an NK cell, and is considered to be an extremely important molecule. In addition, an anti-NKp46 antibody is commercially available as an antibody that exerts an activating effect on an NK cell.

[0054] As for the above-mentioned NK cell surface proteins, molecules that bind to each are known.

[0055] NK cell surface protein: binding molecule (except for anti-X antibody)

[0056] NKp46: Cell Surface Vimentin (CSV)

[0057] NKp30: B7-H6

[0058] NKG2D: MICA, MICB, ULBP1 to 6

[0059] IL-15R: IL-15, IL-2

[0060] IL-2R: IL-15, IL-2

[0061] KIR3DS1: HLA-F, HLA-B

[0062] NKG2C: HLA-E

[0063] NKp80: AICL

[0064] NKp65: KACL

[0065] NKp44: MLL5, PCNA

[0066] LALRA1: HLA-B27 dimer

[0067] LILRA2: soluble HLA

[0068] DNAM-1: CD112, CD155

[0069] Therefore, the region I of the substance of the present application can be selected from any one of the group consisting of CSV, B7-H6, MICA, MICB, ULBP1-6, IL-15, IL-2, IL-15, IL-2, HLA-F, HLA-B, HLA-E, AICL, KACL, MLL5, PCNA, HLA-B27 dimer, soluble HLA, CD112, CD155, and CD48.

[0070] The region I can also be an antibody or an antigen-binding fragment of an antibody capable of binding to the above-mentioned NK cell surface protein. The antigen-binding fragment of an antibody includes a single-chain Fv fragment (scFv), a dimeric scFv (di-scFv), a diabody, a triabody, a tetrabody, a Fab, a F(ab')2, and an Fv.

[0071] In a particularly preferred embodiment, the region I is an antigen-binding domain of an antibody that binds to NKp46, is the region described in the above-mentioned Patent Literature 3, and more specifically, is a sequence represented by SEQ ID NO: 119, 120, 121, or 122 of the sequence listing of the document, and the region I is preferably a polypeptide having the amino acid sequence described by SEQ ID NO: 121 (having an amino acid sequence after the 141st amino acid in the amino acid sequence of SEQ ID NO: 2 of the sequence listing of the present specification).

[0072] Region I can also be a peptide comprising a region of the above-mentioned binding molecule to the NK cell surface protein, i.e., CSV, B7-H6, MICA, MICB, ULBP1-6, IL-15, IL-2, HLA-F, HLA-B, HLA-E, AICL, KACL, ML L5, PCNA, HLA-B27 dimer, soluble HLA, CD112, CD155, and CD48, which is capable of binding to the NK cell surface protein. In the sequence table of the present specification, the region of B7-H6 capable of binding to the NK cell surface protein is described as SEQ ID NO: 3, the region of MICA capable of binding to the NK cell surface protein is described as SEQ ID NO: 4, the region of MICB capable of binding to the NK cell surface protein is described as SEQ ID NO: 5, the region of IL-15 capable of binding to the NK cell surface protein is described as SEQ ID NO: 6, the region of IL-2 capable of binding to the NK cell surface protein is described as SEQ ID NO: 7, the region of HLA-F capable of binding to the NK cell surface protein is described as SEQ ID NO: 8, the region of HLA-B capable of binding to the NK cell surface protein is described as SEQ ID NO: 9, the region of HLA-E capable of binding to the NK cell surface protein is described as SEQ ID NO: 10, the region of CD112 capable of binding to the NK cell surface protein is described as SEQ ID NO: 11, the region of CD155 capable of binding to the NK cell surface protein is described as SEQ ID NO: 12, the region of CSV capable of binding to the NK cell surface protein is described as SEQ ID NO: 32, the region of ULBP1 capable of binding to the NK cell surface protein is described as SEQ ID NO: 33, the region of ULBP2 capable of binding to the NK cell surface protein is described as SEQ ID NO: 34, the region of ULBP3 capable of binding to the NK cell surface protein is described as SEQ ID NO: 35, the region of ULBP4 capable of binding to the NK cell surface protein is described as SEQ ID NO: 36, the region of ULBP5 capable of binding to the NK cell surface protein is described as SEQ ID NO: 37, the region of ULBP6 capable of binding to the NK cell surface protein is described as SEQ ID NO: 38, the region of AICL capable of binding to the NK cell surface protein is described as SEQ ID NO: 39, the region of KACL capable of binding to the NK cell surface protein is described as SEQ ID NO: 40, the region of PCNA capable of binding to the NK cell surface protein is described as SEQ ID NO: 41, and the region of CD48 capable of binding to the NK cell surface protein is described as SEQ ID NO: 42. Also, a polypeptide consisting of a sequence having high sequence identity to any one of these amino acid sequences, or an amino acid sequence in which one or more amino acids in these amino acid sequences are substituted, deleted, inserted, and / or added, and which is capable of binding to the NK cell surface protein can also be used.

[0073] Further, regarding the present application, the number of amino acids in which substitution, etc. occurs in the "amino acid sequence in which one or more amino acids are substituted, deleted, inserted and / or added" is not particularly limited as long as the protein composed of the amino acid sequence has the desired function, and if it is 1 to 9 or 1 to 4 or so, or is substituted with a similar amino acid, a larger number of substitutions, etc. can occur. In addition, regarding the present application, "identity" in the amino acid sequence means the percentage of the number of identical amino acids commonly shared between two sequences out of the total number of positions when the two sequences are optimally aligned. That is, it can be calculated as identity = (number of identical positions / total number of positions) x 100. The search and analysis of the identity of the amino acid sequence can be performed by a known algorithm or program (e.g., BLASTN, BLASTP, BLASTX, ClustalW) by those skilled in the art. The parameters when using the program can be appropriately set if it is those skilled in the art, and in addition, the default parameters of each program can be used. High identity means that the identity is at least 80% or more, preferably 85% or more, more preferably 90% or more, further preferably 95% or more, further preferably 97.5% or more, further preferably 99% or more, further preferably 99.8% or more.

[0074] Region II (capable of binding to an antibody)

[0075] As the region II with the substance of the present application, various protein molecules having antibody-binding property can be selected as long as they do not hinder the binding of the antibody to CD16 (FcyRIII) on the NK cell. As examples of such proteins, ligands having Fc-binding property of IgG can be given, and as examples of the same, Protein A (domains B (Bl, B2, B3, B4, B5) of Staphylococcus aureus, Protein G (domains B (Bl, B2) of group C, domains C (Cl, C2, C3) of group G of Streptococcus, Protein L, Protein Z, Protein LG, Protein LA, Protein AG, PAM, D-PAM, D-PAM-F, TWKTSRISIF, FGRLVSSIRY, Fc-III, Fc-III- (Sepharose) FcBP-2, Fc-III-4C, EPIHRSTLTALL, APAR, FcRM, HWRGWV, HYFKFD, HFRRHL, cyclo[(Nα-Ac)S(A)-, RWCitGWV, D2AAGDAAG, RWHYFK-Lact-E], cyclo[(Nα-Ac)-Dap(A)-RWHYFK-Lact-E], cyclo[(Nα-Ac)S(A)-RWHYFK-Lact-E], cyclo[Link-M-WFRHYK], NKFRGKYK, NARKFYKG, FYWHCLDE, FYCHWALE, FYCHTIDE, Dual 1 / 3, RRGW, KHRFNKD, Fc-III peptide (a cyclic peptide having a function of making the interaction between CH2 and CH3 in the Fc region of IgG by binding of the thiol groups in the cysteine residues via disulfide bonds.International Publication No. 2001 / 045746, Science, 2000, Vol. 287, pp. 1279-1283) or a mutant thereof (Japanese Patent Application Publication No. 2016-88906), YYWLHH, AV13 (GFRKYLHFRRHLL), and AV15 (VRLGWLLAPADLDAR) (U.S. Patent No. 7408030), FcRM peptide (Chem Bio Chem, 2005, Vol. 6, pp. 1242-1253), histidine (J Chromatography, 1992, Vol. 604, pp. 29-37), TG19318 (J Molecular Recognition, 1998, Vol. 11, PP. 128-133), TG19320 (J Immunological Methods, 2002, Vol. 271, pp. 77-88), IMG4K6R peptide (International Publication No. 2013 / 027796, J Biol Chem, 2009, Vol. 284, pp. 9986-9993), IgA-binding peptide (International Publication No. 2011 / 148952, J Biol Chem, 2012, Vol. 287, pp. 43126-43136). For the Fc-binding ligand of IgG, the person skilled in the art can refer to Materials 2016, 9, 994; doi:10.3390 / ma9120994.

[0076] Region II can also be an antibody or an antigen-binding fragment of an antibody. The antigen-binding fragment of an antibody includes a single-chain Fv fragment (scFv), a dimeric scFv (di-scFv), a diabody, a triabody, a tetrabody, a Fab, a F(ab’)2, an Fv.

[0077] Region II can be a region that specifically binds to the Fc site of IgG using a cross-linking agent. The cross-linking agent is a chemical substance for linking the IgG-binding peptide to the IgG Fc through a covalent bond. The cross-linking agent of the present application can be appropriately selected if it is a person skilled in the art, and can be set to a compound having at least two sites capable of binding to a desired amino acid (e.g., lysine residue, cysteine residue, aspartic acid residue, glutamic acid residue, 2-aminooctanedioic acid, or diaminopropionic acid, arginine, etc.). As examples thereof, without limitation, there can be mentioned a cross-linking agent preferably containing two or more succinimidyl groups such as DSG (Disuccinimidyl glutarate), DSS (Disuccinimidyl Suberate), etc., a cross-linking agent preferably containing two or more imide acid moieties such as DMA (Dimethyl Adipimidate Dihydrochloride), DMP (Dimethyl Pimelimidate Dihydrochloride), and DMS (Dimethyl Suberimidate Dihydrochloride), and a cross-linking agent having an SS bond such as DTBP (Dimethyl 3,3'-Dithiobispropionimidate Dihydrochloride) and DSP (Dithiobis(Succinimidyl Propionate)). The IgG-binding peptide modified by the cross-linking agent can be added to IgG in a short time and with almost no side reaction.

[0078] In this case, region II has an amino acid residue capable of reacting with a cross-linking agent in its sequence. Examples of such an amino acid residue are lysine residue, cysteine residue, aspartic acid residue, and glutamic acid residue, and the like protein-constituting amino acids, and diaminopropionic acid and 2-aminooctanedioic acid, and the like non-protein-constituting amino acids, and is preferably lysine residue. Region II preferably has no or almost no (e.g., only one or two) other residues identical to the amino acid residue capable of reacting with the cross-linking agent in its sequence. For example, when the amino acid residue capable of reacting with the cross-linking agent is lysine residue, the peptide of the present application preferably has no or almost no lysine residue in its sequence at a position other than the amino acid residue that reacts with the cross-linking agent.

[0079] Particularly preferred examples of such peptides having Region II with amino acid residues capable of reacting with a crosslinking agent are peptides having the sequences set forth as SEQ ID NOs: 1 to 17, 36, and 37 in the sequence listing of WO2016 / 186206. These are set forth as SEQ ID NOs: 13 to 29, 30, and 31, respectively, in the sequence listing of the present specification. Likewise, polypeptides consisting of a sequence having high sequence identity with any one of these amino acid sequences, or an amino acid sequence in which one or more amino acids in these amino acid sequences are substituted, deleted, inserted, and / or added, and capable of binding to an NK cell surface protein can also be used.

[0080] Such a peptide binds to the Fc domain of IgG. In addition, it approaches a specific region of IgG Fc, i.e., the Lys248 residue (corresponding to the 18th residue of human IgG CH2) or the Lys246 residue (corresponding to the 16th residue of human IgG CH2) according to Eu numbering in human IgG Fc, preferably the Lys248 residue.

[0081] The reaction using such a crosslinking agent can be performed with reference to the above-mentioned WO2016 / 186206. In addition, an example of this experimental protocol is shown below.

[0082] [Chemical Formula 1]

[0083]

[0084] Region II can also be an aptamer and a low-molecular compound that recognize the Fc region. In the range capable of recognizing the Fc region, the aptamer can also be a mutant. As the aptamer that recognizes the Fc region, a human IgG aptamer (International Publication No. 2007 / 004748, RNA, 2008, Vol. 14, pp. 1154-1163), etc. can be mentioned. As the low-molecular compound that recognizes the Fc region, a mannose erythritol lipid (J Biomedical Materials Res. A, 2003, Vol. 65, pp. 379-385), a transition metal ion (J Appl Polym Sci, 89, 1567-1572, J Chromatography B, 2003, Vol. 795, pp. 93-103), an aromatic amine (J Chromatography B, 2000, Vol. 740, pp. 1-15), sulfamerazine (J Chromatography B, 2003, Vol. 792, PP. 177-185), etc. can be mentioned.

[0085] The substance of the present application can have a linker portion connecting region I and region II. The linker portion can take various structures as long as region I is capable of binding to a surface protein of an NK cell and region II is capable of binding to an antibody and does not hinder the binding of the antibody to CD 16 (FcyRIII) on the NK cell.

[0086] The linker is, for example, a flexible linker, and is a peptide linker of 2 to 31 amino acids in length. For example, the linker sequence is about 16 amino acids in length. As examples of preferred linkers, there are mentioned a peptide consisting of any one of the sequences (G4S) x 3, or GGGGSGGGGSGGGGS (GS16), SG(GS2), SGGGGS (GS6), SGGGGSGGGGSGGGGSGGGGSGGGGSGGGGS (GS31).

[0087] In a preferred embodiment, the linker is a rigid linker. For example, the rigid linker comprises the sequence (EAAAK)n, where n is 1 to 3. In one example, the rigid linker comprises (EAAAK)n, where n is 1 to 10 or about 1 to 100. For example, n is at least 1, or at least 2, or at least 3, or at least 4, or at least 5, or at least 6, or at least 7, or at least 8, or at least 9, or at least 10. In one example, n is less than 100. For example, n is less than 90, or less than about 80, or less than about 60, or less than about 50, or less than about 40, or less than about 30, or less than about 20, or less than about 10.

[0088] In a preferred embodiment, the linker is a cleavable linker. For example, the linker can be cleaved by a protease or a peptidase.

[0089] (PREFERRED EMBODIMENTS)

[0090] The amino acid sequence and the polynucleotide sequence encoding the same of a particularly preferred embodiment of the substance of the present application when it is a fusion protein are shown in Figure 6 and the sequence listing.

[0091] (NK CELLS)

[0092] In general, an NK cell is a large granular lymphocyte that does not express a T cell receptor (TCR), a T cell universal marker CD3, and a B cell receptor as a membrane immunoglobulin, and is generally CD16-positive and CD56-positive in humans. Whether or not a cell is an NK cell can be easily determined by those skilled in the art based on the expression pattern of cell surface markers, etc. An NK cell has cytotoxic activity, and the presence or absence or degree of the cytotoxic activity can be determined by various known methods.

[0093] As for the present application, the NK cell includes the above general NK cell except for the specifically described case, and the NK cell also includes peripheral blood NK cell, umbilical cord blood NK cell, primary NK cell, cultured NK cell, high activity NK cell, and the NK cell or NK-like cell of [1], [2], [3], and [4] below.

[0094] [1] NK cell having the following (1) and (2) characteristics:

[0095] (1) CD16 positive, CD56 highly expressed, and CD57 negative.

[0096] (2) NKG2C positive, NKG2A negative to low expression, and CD94 positive.

[0097] The high activity NK cell of [1] can be CD16 highly expressed. In addition, the high activity NK cell of [1] can further have the following characteristics regardless of whether it is CD16 highly expressed or not.

[0098] (3) Cytotoxic activity of 50% or more when the NK cell is co-cultured as an effector cell (E) and K562 cells are co-cultured as a target cell (T) at a mixed ratio (E:T) of 1:1.

[0099] The high activity NK cell of [1] can also be expressed as follows:

[0100] NK cell having the following (1) and (3) characteristics obtained in the following manner:

[0101] CD3 positive cells are removed from peripheral blood mononuclear cells from healthy people using CD3 beads (e.g., CliniMACS CD3, Miltenyi Biotec, catalog number 130-017-601), LD columns (e.g., Miltenyi Biotec, catalog number 130-042-901), and separation buffer (e.g., PBS containing 0.5% human AB serum (non-activated treated), 2mM EDTA), and the obtained cell population is cultured in an appropriate medium (e.g., COS-008 added with 5% human AB serum (non-activated treated)) for 14 days, thereby obtaining NK cells.

[0102] (1) CD16 positive, CD56 highly expressed, and CD57 negative.

[0103] (3) Cytotoxic activity of 50% or more when the NK cell is co-cultured as an effector cell (E) and K562 cells are co-cultured as a target cell (T) at a mixed ratio (E:T) of 1:1.

[0104] Detailed, more specific preparation methods of the characteristics of the high-activity NK cells of [1] can be referred to Japanese Patent Application Publication No. 2018-193303.

[0105] [2] the following cells:

[0106] cells that are CCR5-positive, CCR6-positive, CXCR3-positive, and CD3-negative.

[0107] The cells of [2] can also be CD11c-highly-expressing.

[0108] The cells of [2] can also be expressed as follows:

[0109] cells that are CCR5-positive, CCR6-positive, CXCR3-positive, Integrin a1-positive, Integrin a3-positive, Integrin b3-negative, and CD3-negative. Alternatively, cells that are CCR5-positive, CCR6-positive, CXCR3-positive, CD11a-highly-expressing, CD11c-highly-expressing, and CD3-negative. Here, the highly-expressing is judged by comparison with the expression of a population of NK cells obtained from peripheral blood, which has not been substantially cultured.

[0110] According to the research by the present inventors, the cells of [2] show extremely high cytotoxic activity against solid cancer that forms a tumor mass. Detailed, more specific preparation methods of the characteristics of the cells of [2] can be referred to Japanese Patent Application Publication No. 2019-170176.

[0111] [3] high-activity NK cells that can be obtained by the following method:

[0112] To mononuclear cells obtained from fresh peripheral blood or frozen apheresis blood, CD3 beads (e.g., CliniMACS CD3, Miltenyi Biotec, 130-017-601 (1 x 10 7 cells 5 pL), and, when using frozen separation blood, further add CD34 beads (e.g., CliniMACS CD34, Miltenyi Biotec, 130-017-501 (1 x 10 7 cells 2.5 pL), suspend, and, after incubation at 4°C for 15 minutes, add separation buffer (e.g., PBS containing 0.5% human AB serum (non-activated treatment at 56°C for 30 minutes), 2 mM EDTA), suspend well, and centrifuge. Remove the supernatant, and, per 1 LD column (e.g., Miltenyi Biotec, 130-042-901), the maximum number of cells is 1 x 10 8The cells were suspended in 0.5 mL of separation buffer. After 2 mL of separation buffer was added in advance, the cell suspension was added to the LD column, and the eluate from the LD column was recovered. Further, 1 mL of separation buffer was added to the LD column, and the eluate was recovered. The recovered liquid was centrifuged, and after the supernatant was removed, the cells were suspended in 1 mL of KBM501 medium containing 5% human AB serum (non-activated by heating at 56°C for 30 minutes) or 2 U / mL of heparin sodium added to 5% UltraGRO (AventaCell, HPCPLCRL10) at a concentration of 5 x 10 5 The cells were suspended in 0.5 mL of separation buffer. After 2 mL of separation buffer was added in advance, the cell suspension was added to the LD column, and the eluate from the LD column was recovered. Further, 1 mL of separation buffer was added to the LD column, and the eluate was recovered. The recovered liquid was centrifuged, and after the supernatant was removed, the cells were suspended in 1 mL of KBM501 medium containing 5% human AB serum (non-activated by heating at 56°C for 30 minutes) or 2 U / mL of heparin sodium added to 5% UltraGRO (AventaCell, HPCPLCRL10) at a concentration of 5 x 10 6 The cells were suspended in 0.5 mL of separation buffer. After 2 mL of separation buffer was added in advance, the cell suspension was added to the LD column, and the eluate from the LD column was recovered. Further, 1 mL of separation buffer was added to the LD column, and the eluate was recovered. The recovered liquid was centrifuged, and after the supernatant was removed, the cells were suspended in 1 mL of KBM501 medium containing 5% human AB serum (non-activated by heating at 56°C for 30 minutes) or 2 U / mL of heparin sodium added to 5% UltraGRO (AventaCell, HPCPLCRL10) at a concentration of 5 x 10

[0113] The specific method for preparing the high-activity NK cells of [3] can be found in the specification of Patent Application No. 2020-35297.

[0114] [4] The cells obtained in the following manner. When the cells of [1] to [3] are obtained, any one selected from the group consisting of IL-12, IL-15, and IL-18 is added at a concentration that can achieve the object of the present application, together with IL-2 or instead of IL-2, and the cells are cultured to obtain the cells. The specific method for preparing such cells can be found in Leong JW et al. Biol Blood Marrow Transplant 20 (2014) 463-473.

[0115] Further, the present application is described in the present specification using the case where the high-activity NK cells are used as an example, but if it is a person skilled in the art, the present application can be understood based on the description thereof also for the case where other cells that are activated by using any cytokine in vitro are used.

[0116] (Cytotoxic activity)

[0117] As for the high-activity NK cells and the like in the present application, the activity or the cytotoxic activity means the ability of the target cells (effector cells, E) to lyse the target cells (T) except for the case where it is specifically described. The cytotoxic activity can be expressed as the percentage (%) of the target cells that are killed by the effector cells, and is calculated by the following formula.

[0118] (Cell death when co-cultured with effector cells - natural cell death (negative control) / (maximum cell death (positive control) - natural cell death (negative control) x 100

[0119] In measuring cytotoxic activity, the mixing ratio of effector cells to target cells (E:T), and the time for which effector cells and target cells are co-cultured can be appropriately set depending on the kind of cells used or the strength of activity, based on the degree of cytotoxic activity of effector cells, and the like. When NK cells are used as effector cells, there are cases in which the target cells are K562 cells, acute myelogenous leukemia cells, chronic myelogenous leukemia cells, but the present application is not limited thereto. Effector cells and target cells, and living cells and dead cells can be distinguished and quantified by reagents such as antibodies labeled with radioactive substances, fluorescent dyes, and the like. Cytotoxic activity when NK cells are used as effector cells can be measured under conditions in which K562 cells are used as target cells, E:T is set to 1:0.05 to 10, preferably 1:0.1 to 5, more preferably 1:1, and the incubation time is set to 0.5 to 18 hours, preferably 1 to 12 hours.

[0120] With respect to the present application, the activity of NK cells and the like is high, and, except for specifically described cases, means that the cytotoxic activity is 50% or more when target cells are K562 cells, mixed at E:T = 1:1, and incubated for 0.5 to 3 hours, more specifically 2 hours. The activity is preferably 60% or more, and more preferably 70% or more.

[0121] With respect to the present application, a certain cell (for example, a cell other than an antigen tumor cell, a normal cell) is not killed by NK cells and the like, and, except for specifically described cases, means that the cytotoxic activity is less than 5% when target cells are T, mixed at E:T = 1:1, and incubated for 0.5 to 3 hours, more specifically 2 hours. The activity with respect to target cells is preferably less than 3%, and more preferably less than 1% or not detected.

[0122] [Method for preparing NK cell population]

[0123] The present application also provides a method for preparing an NK cell population, comprising the following steps.

[0124] (1) preparing an NK cell population, an antibody, and a substance having region I capable of binding to a surface protein of an NK cell and region II capable of binding to the antibody;

[0125] (2) adding the antibody to the NK cell population in the presence of a protein, to obtain an NK cell population bound to the antibody;

[0126] At this time, the NK cell binds to region I of the substance, and the antibody binds to region II of the substance, and the substance stabilizes the binding of the NK cell to the antibody.

[0127] (Step (1): preparation of an NK cell population and the like)

[0128] The starting material of the NK cell population can be peripheral blood, umbilical cord blood, bone marrow and / or lymph node, blood collected by apheresis (separated blood). In addition, the starting material can be a material prepared from at least one cell selected from the group consisting of: hematopoietic stem cells from any one stem cell selected from the group consisting of embryonic stem cells, adult stem cells, and artificial pluripotent stem (iPS) cells; hematopoietic stem cells from umbilical cord blood; hematopoietic stem cells from peripheral blood; hematopoietic stem cells from bone marrow blood; umbilical cord blood mononuclear cells; peripheral blood mononuclear cells. The donor of the starting material can be the patient himself / herself who receives immunotherapy using high-activity NK cells and the like, a close relative of the patient, or a healthy person who has no blood relationship with the patient. The donor can be plural.

[0129] (culture medium)

[0130] For obtaining the NK cell population, the culture medium for culturing and activating the cells as the starting material includes KBM501 medium (Kohjin Bio, Inc., containing IL-2 at 1.750 JRU / mL), COS-008 (Cosmo Bio, containing IL-2 at 1.750 JRU / mL), FKCM101 (Fukoku, containing no IL-2 or containing IL-2 at 175 IU / mL), CellGro SCGM medium (CellGenix, Iwaki Chemicals), X-VIVO 15 medium (Lonza, Takara Bio, Inc.), Gibco (registered trademark) CTS (registered trademark) AIM V (registered trademark) medium (Thermo Fisher Scientific, known serum-free medium for proliferation and manipulation of T cells and dendritic cells), CTS OpTmizer T Cell Expansion Basal Medium (Thermo Fisher Scientific, for growth and proliferation of human T lymphocytes), IMDM, MEM, DMEM, RPMI-1640, and the like, but is not limited thereto. Preferred examples are KBM501 medium, FKCM101, or COS-008. Furthermore, with respect to the present application, the culturing of cells (culturing cells) means, except for specifically described cases, maintaining cells in a culture medium or a liquid based thereon for a certain period of time for any one purpose selected from the group consisting of survival maintenance of cells, expansion of cells, and activation of cells. When a certain period of time of treatment is performed at a certain temperature, it is sometimes referred to as incubation (incubating).

[0131] In the culture medium, IL-2 can be added at a concentration that can achieve the object of the present application. The concentration of IL-2 can be 2500 IU / mL to 2813 IU / mL. IL-2 preferably has a human amino acid sequence, and is preferably produced by recombinant DNA technology for safety. The concentration of IL-2 can be expressed in domestic standard units (JRU) and international units (IU). Since 1 IU is about 0.622 JRU, 1750 JRU / mL of the existing culture medium corresponds to about 2813 IU / mL.

[0132] Any one selected from the group consisting of IL-12, IL-15, and IL-18 can be added at a concentration that can achieve the object of the present application, simultaneously with IL-2 or instead of IL-2 (Leong JW et al. Biol Blood Marrow Transplant 20 (2014) 463-473). Each concentration can be 1 pg / mL to 1 pg / mL regardless of the presence or absence of other cytokines or the concentration thereof. IL-2 preferably has a human amino acid sequence, and is preferably produced by recombinant DNA technology for safety.

[0133] In the culture medium, the subject's own serum, human AB serum available from BioWhittaker, Inc., or blood donor serum albumin available from the Japanese Red Cross Society can be added. The own serum and human AB serum are preferably added at a concentration of 1 to 10%, and the blood donor serum albumin is preferably added at a concentration of 1 to 10%. Human platelet lysate (HPL) can also be added together with the serum or instead of the serum. HPL is commercially available, and the UltraGRO™ series (AventaCell BioMedical, Inc.) is sold. When HPL is used, sodium heparin can be further added to the culture medium.

[0134] In the culture medium, appropriate proteins, cytokines, antibodies, compounds, and other components can be included without impairing the culture effect of NK cells. The cytokines can be IL-3, IL-7, IL-21, stem cell factor (SCF), and / or FMS-like tyrosine kinase 3 ligand (Flt3L) in addition to IL-2, IL-12, IL-15, and IL-18 described above. Each of these preferably has a human amino acid sequence, and is preferably produced by recombinant DNA technology for safety.

[0135] The culture medium is preferably a serum-free medium. The serum-free medium preferably contains serum albumin, transferrin, and insulin. Serum-free media for culturing lymphocytes have been developed and are commercially available, and these can be used in the present application. One preferred example of a serum-free medium is a medium obtained by adding CTS Immune Cell SR (thermo fisher scientific), which is commercially available as a composition for supporting the proliferation of human T cells, to a basal medium.

[0136] The medium exchange or supplementation can be performed at any time after the start of the culture under conditions in which the target culture effect is obtained, but is preferably performed every 3 to 5 days.

[0137] The culture vessel used in the culture includes commercially available culture dishes, flasks, plates, and multi-well plates, but is not limited thereto. The culture conditions are not particularly limited as long as the culture effect of the NK cells is not impaired, but are generally 37°C, 5% CO2, and a saturated water vapor atmosphere. The culture period is not particularly limited as long as the target culture effect is obtained.

[0138] (Antibodies, antibody drugs)

[0139] In the present application, the antibody refers to any one of the types (isotypes) of immunoglobulins, unless otherwise specifically described. In the case of humans, the antibodies have five types, IgG, IgM, IgA, IgD, and IgE. In addition, in the present application, the antibody includes antibody drugs having a sequence from an antibody, unless otherwise specifically described. In the present application, the antibody drug is not limited in terms of the source of the organism, unless otherwise specifically described. The antibody drug used in the present application can be a mouse antibody, a chimeric antibody, a humanized antibody, a human antibody, or an antibody that does not have a sub-stem system indicating the source. In the present specification and the accompanying drawings, the case where the antibody is IgG is exemplified for the explanation of the present application, but the explanation can be understood by those skilled in the art even if other types of antibodies are used.

[0140] (IgG)

[0141] In the present application, IgG includes molecules derived from IgG, in addition to IgG, unless otherwise specifically described. The molecules derived from IgG include antibody fragments. As examples, Fab, scFv, V H -V L , scFv-C H3、VhH, Dab, their multimers, their fusions. (Nature Biotechnology volume 23, pages 1126-1136 (2005)). IgG-derived molecules also include single domain antibodies. As this example, VHH, VNAR, sdAb can be cited. Single domain antibodies can selectively bind to specific antigens, and are low molecular weight compared to IgG and Fab, scFv, and the like antibody fragments. VHH antibody (variable domain of heavy chain of heavy chain antibody, heavy chain variable region of heavy chain antibody) is a variable region of an antibody (heavy chain antibody) composed only of H chain of Camelidae (llama, alpaca, etc.), has high stability, can be produced at low cost, and is expected to be used as an antibody medicine (Front Immunol. 2017 Jun 9; 8: 653.).

[0142] As for the present application, IgG also includes antibody drugs having sequences from IgG. As examples of antibody drugs having IgG or sequences from IgG, muromonab-CD3, ibritumomab tiuxetan, iodine 131Tositumomab, catumaxomab, blinatummab, moxetumomab pasudotox, abciximab as a chimeric antibody, rituximab, basiliximab, infliximab, cetuximab, brentuximab vedotin, siltuximab, dinutuximab, obiltoxaximab, daclizumab as a humanized antibody, palivizumab, trastuzumab, gemtuzumab ozogamicin, alemtuzumab, omalizumab, efalizumab, bevacizumab, natalizumab, tocilizumab, ranibizumab, eculizumab, certolizumab pegol, mogamulizumab, pertuzumab, trastuzumab emtansine, obinutuzumab, vedolizumab, pembrolizumab, idarucizumab, mepolizumab, elotuzumab, ixekizumab, reslizumab, atezolizumab, ocrelizumab, inotuzumab ozogamicin, and the like can be given.ozogamicin), emicizumab, benralizumab, galcanezumab, fremanezumab, tildrakizumab, caplacizumab, ibalizumab, ravulizumab, romosozumab, risankizumab, adalimumab as a human antibody, panitumumab, golimumab, ustekinumab, canakinumab, ofatumumab, denosumab, ipilimumab, belimumab, raxibacumab, ramucirumab, nivolumab, secukinumab, evolocumab, alirocumab, necitumumab, daratumumab, brodalumab, olaratumab, bezlotoxumab, avelumab, durvalumab, dupilumab, bezlotoxumab, guselkumab, sarilumab, burosumab, erenumab, lanadelumab, emapalumab as an antibody without a sub-stem system indicating the source.

[0143] The antibody drug used in the present application is preferably an antibody drug for treating cancer or infectious diseases.

[0144] (Step (2): Stabilization of the binding of the antibody to the NK cell)

[0145] In this invention, the process involves adding an antibody to an NK cell population in the presence of the substance of this invention to obtain an NK cell population bound to the antibody. During this process, the NK cells bind to region I of the substance, and the antibody binds to region II of the substance, thus stabilizing the binding of the NK cells to the antibody. The mixing of the NK cell population, the antibody, and the substance of this invention can be performed at the time of use. For example, the NK cell population, the antibody, and the substance can be kept in separate containers and mixed several hours before administration to the target.

[0146] The mixing order can be set appropriately. For example, the NK cell population can be mixed with the substance and incubated before adding the antibody for further incubation, or the NK cell population can be mixed with the substance and incubated before adding the antibody for further incubation.

[0147] In the method for preparing an NK cell population, there may be a step to remove antibodies that do not bind to NK cells. That is, the NK cell population obtained by this preparation method contains NK cells and antibodies, but preferably all antibodies bind to NK cells, and substantially does not contain antibodies that do not bind to NK cells.

[0148] [Pharmaceutical Composition]

[0149] The present invention also provides a pharmaceutical composition comprising a population of NK cells bound to an antibody drug, wherein the binding of the antibody drug to the NK cells is stabilized by a substance having the following regions.

[0150] Region I, which can bind to the surface proteins of NK cells; and

[0151] Region II, which can bind to antibodies.

[0152] Typically, the pharmaceutical composition consists of NK cells suspended in solution, bound to an antibody and stabilized by the antibody. Solutions used to suspend NK cells are generally, for example, cryoprotectants containing DMSO, physiological saline, phosphate-buffered saline (PBS), culture media, serum, etc. The solution may contain pharmaceutically acceptable carriers for use in drugs and skincare products.

[0153] The preparation of the pharmaceutical composition of the present invention is preferably carried out under conditions that comply with the rules for the preparation and quality management of pharmaceuticals and skin care products (good manufacturing practice, GMP) and the benchmarks for the preparation and quality management of regenerative medicine and other products (Good Gene, Cellular, and Tissue-based Products Manufacturing Practice, GCTP).

[0154] The pharmaceutical composition according to the present application can be used for the treatment of various diseases having sensitivity to highly active NK cells and the like. Examples of such diseases include cancer or infectious diseases, specifically, skin cancer, oral cancer, gallbladder cancer, bile duct cancer, lung cancer, liver cancer, stomach cancer, large intestine cancer, pancreatic cancer, kidney cancer, ovarian cancer, bladder cancer, prostate cancer, neuroblastoma, leukemia, or infectious diseases caused by viruses, bacteria, and the like, but are not limited thereto.

[0155] The cell therapy using the pharmaceutical composition according to the present application can be performed alone or in combination with surgical therapy, chemotherapy, radiation therapy, antibody drugs, and the like.

[0156] An important insight obtained in the present application is that NK cells do not completely kill normal cells even when activated in vitro, regardless of whether or not they are combined with antibody drugs. This insight shows that by limiting the effector cells of the ADCC activity of antibody drugs to NK cells, the advantages of the ADCC activity can be maintained, and the safety of antibody drugs can be improved. When NK cells are present only in peripheral blood, the number and activity thereof are small for the treatment of malignant tumors or infectious diseases, and thus it is preferable to activate them in vitro. According to this insight, NK cells activated in vitro can be limited to the effector cells of the ADCC activity of antibody drugs, and antibody drugs and highly active NK cells can be more easily used in therapy. In particular, this insight is particularly important in terms of safety when highly active NK cells are used. Examples

[0157] [Methods Common to Experiments and Examples]

[0158] A). Culture method of highly active NK cells GAIA-102

[0159] Frozen apheresis blood (HemaCare, PB001CLP) was thawed, washed and concentrated using a Lovo cell processing system (FRESENIUS KABI) to obtain PBMCs. CD3 beads ※1 , CD34 beads ※2 were added to the obtained PBMCs, and suspended, and after incubation at 4°C for 15 minutes, separation buffer ※3 was added, and suspended, and centrifuged at 300 x g for 10 minutes. The supernatant was removed, and the number of cells per 1 LD column (Miltenyi Biotec, 130-042-901) was maximized to 1 x 10 8Cells were suspended in 0.5 mL of separation buffer. After adding 2 mL of separation buffer, the cell suspension was added to the LD column, and the eluent from the LD column was recovered. Another 1 mL of separation buffer was added to the LD column, and the eluent was recovered. Then, the column was washed with 1 mL of separation buffer, and the number of cells in the recovered liquid was counted to calculate the total number of cells. The cells were centrifuged at 500 × g for 5 minutes, the supernatant was removed, and the cells were cultured, or cultured using a STEM-CELLBANKER at 1 x 10⁻⁶ cells / mL. 7 Cells / mL were frozen at -80°C to remove CD3 and CD34 from PBMCs. When using frozen PBMCs for culture, they were thawed with serum-containing medium diluted 10-fold and culture was started.

[0160] The cultivation is carried out in the following manner, namely, to become 1x10 6 Cells were suspended in KBM501 medium at a rate of 1 / mL. ※4 The culture was conducted using 6-well plates (Thermo Fisher Scientific, 140675), T-75 flasks (Thermo Fisher Scientific, 156499), or adhesive culture bags (Nipro) in a CO2 incubator (37°C, 5% CO2). On day 9 of culture, KBM501 medium was added at a final volume of 6 mL per well for 6-well plates, 50 mL per well for T-75 flasks, and 500 mL per bag for adhesive culture bags, and incubated until day 14.

[0161] ※1: CliniMACS CD3, Miltenyi Biotec, 130-017-601 (per 1x10) 7 5 μL of cells)

[0162] ※2: CliniMACS CD34, Miltenyi Biotec, 130-017-501 (per 1x10 7 2.5 μL of cells

[0163] ※3: PBS (Nacalai Tesque, 14249-24) containing 0.5% human AB serum (Cosmo Bio, 12181301, deactivated at 56°C for 30 minutes) and 2 mM EDTA (Thermo Fisher Scientific, 15575-020).

[0164] ※4: KBM501 (Kohjin Bio, 16025015) containing 5% human serum type AB (Cosmo Bio, 12181301, non-activated for 30 minutes at 56°C) or 2 U / mL heparin sodium added to 5% UltraGRO (AventaCell, HPCPLCRL10)

[0165] B). Recovery method of highly active NK cells GAIA-102

[0166] The culture solution was recovered on day 14 of the culture, and further 1 mM EDTA was added to the culture vessel, the adherent cells were peeled off, and the culture vessel after peeling off the cells was washed with KBM501 medium. After centrifugation of all the cell recovery solution, it was washed and resuspended with KBM501 medium.

[0167] C). Confirmation of binding of GAIA-102 to antibody drugs

[0168] For GAIA-102 reacting with each antibody drug, after staining in an antibody solution in which each of the antibodies shown below was mixed at a concentration of 1 pg / mL at 4°C for 30 minutes, centrifugation (500 x g, 5 minutes) was performed, the supernatant was removed, and after resuspension in PBS, measurement was performed using a flow cytometer (BD LSRFortessa, BD Biosciences), and analysis was performed using FlowJo software (FLOWJO, LLC).

[0169] <Antibodies used>

[0170] Alexa Fluor (registered trademark) 700-labeled anti-human CD56 antibody (Biolegend, 318316), PerCP / C5.5-labeled anti-human CD3 antibody (Biolegend, 300430), PE-Cy7-labeled anti-human CD16 antibody (Biolegend, 302016), PE-labeled anti-human IgG antibody (SouthernBiotech, 2043-09)

[0171] [Experiment 1: Confirmation of killing of Allo-9WBC when using antibody drugs in combination]

[0172] The number of viable cells of the NK cells obtained according to the procedure described in B) above was counted, and 1 x 10 7 The cells were suspended in 1 mL of STEM-CELLBANKER, frozen at -80°C, thawed in a water bath at 37°C, diluted 10-fold with PlasmaLyte-A, and after storage at room temperature for 1 hour, cultured in KBM501 medium for 3 hours.

[0173] For the determination of cytotoxic activity, a group of thawed NK cells and K562 cells were prepared, a group of K562 cells alone as a negative control, and a group of K562 cells fixed with 10% formalin as a positive control.

[0174] NK

[0175] The cells cultured for 3 hours after thawing described above were recovered, adjusted to a concentration of 2 x 10 6 cells / ml with 10% FBS / RPMI1640.

[0176] Tumor cell line

[0177] K562 cells (human chronic myelogenous leukemia cell line), Hut78 cells (human T lymphoma (Sezary syndrome)) were suspended in RPMI1640 medium without serum components, stained using a PKH26 red fluorescent cell linker kit (Sigma, PKH26 GL-1KT), and finally adjusted to a concentration of 2 x 10 6 cells / mL with 10% FBS / RPMI1640.

[0178] PBMC

[0179] Peripheral blood mononuclear cells (PBMCs) were prepared using the cells obtained by the above-described procedure of A). They were suspended in RPMI1640 medium without serum components, stained using a PKH67 green fluorescent cell linker kit (Sigma, PKH67 GL-1KT), and finally adjusted to a concentration of 2 x 10 6 cells / mL with 10% FBS / RPMI1640.

[0180] NK cells and K562 cells, PBMCs were added to a 96-well plate (IWAKI, 4870-800SP) at a cell ratio of 1:1 or 1:1:1, and for Poteligeo (+), Poteligeo was added at a final concentration of 10 μg / ml and mixed, and reacted for 2 hours at 37°C, 5% CO2. After the reaction, centrifugal separation was performed (500 x g, 5 minutes), and after removing the supernatant, a 7-AAD solution diluted with PBS was added to suspend, and incubated for 20 minutes at room temperature. Using a flow cytometer, the cytotoxic activity (% lysis) was calculated using FlowJo software.

[0181] ※5: Cytotoxic activity (% lysis) = (cell death rate - negative control cell death rate) / (positive control cell death rate - negative control cell death rate) x 100

[0182] The results are shown in Figure 1 Even when Poteligeo was used in combination, no killing of PBMC was found.

[0183] [Experiment 2: Maintenance of NK cells against antibody drugs in culture medium]

[0184] The viable cell number of GAIA-102 obtained according to the steps described in the culture method of highly active NK cells, the recovery method was counted so as to be 1 x 10 6 The suspended GAIA-102 was inoculated into a low-adsorption 6-well plate (IWAKI, 4810-800SP) and left to stand at room temperature for 1 hour. After 1 hour of reaction, the cells were recovered and washed with PBS three times, and the GAIA-102 suspended in PBS + mogamulizumab, the GAIA-102 suspended in KBM501 medium (5% UltraGRO + 2 U / mL sodium heparin) were subjected to antibody staining and measurement according to the steps described in C), and the presence or absence of binding of GAIA-102 to mogamulizumab was analyzed when CD16lowand CD16highin the cell population showing CD56+and CD3-.

[0185] The results are shown in Figure 2 It was found that GAIA-102 could not maintain the antibody through CD16 in KBM501 medium.

[0186] [Experiment 3: Effect of culture medium additives]

[0187] GAIA-102 and 100 μg / mL mogamulizumab were reacted at room temperature for 1 hour according to the same steps as in Experiment 2. After washing with PBS three times, they were divided into five groups, and (1) KBM501 medium (5% UltraGRO + 2 U / mL sodium heparin), (2) KBM501 medium without serum components (hereinafter referred to as serum-free KBM501 medium), (3) 10% FBS / RPMI1640 medium containing 3,000 IU / mL IL-2 (Imunace (注册商标) , Shionogi Pharmaceutical) were added, and the reaction was carried out at room temperature for 1 hour. After 1 hour of reaction, the cells were recovered and washed with PBS three times, and the GAIA-102 suspended in PBS + mogamulizumab, the GAIA-102 suspended in KBM501 medium (5% UltraGRO + 2 U / mL sodium heparin) were subjected to antibody staining and measurement according to the steps described in C), and the presence or absence of binding of GAIA-102 to mogamulizumab was analyzed when CD16lowand CD16highin the cell population showing CD56+and CD3-. ※5, (5) PBS. After each group was left to stand for about 5 minutes, antibody staining and measurement were performed according to the procedure described in C), and analysis was performed on the presence or absence of binding of GAIA-102 and moximilomab at CD16low and CD16high in the CD56+ and CD3- cell population.

[0188] ※5: RPMI1640 medium containing 10% FBS (Nichirei Bioscience, 171012-500ML) and 100 units of penicillin, 100 pg / mL of streptomycin (Nacalai Tesque, 26253-84)

[0189] The results are shown in Figure 3 . It was found that GALA-102 could not be held by CD16 with an antibody in the medium containing UltraGro.

[0190] [Experiment 4: Effects in blood]

[0191] GAIA-102 and 100 pg / mL of moximilomab were allowed to react at room temperature for 1 hour according to the same procedure as in Experiment 2. After washing 3 times with PBS, they were divided into 8 groups, and were placed in (1) 10% FBS / KBM501 medium, (2) 5% UltraGRO / KBM501 medium, (3) 1% UltraGRO / KBM501 medium obtained by diluting 5 times at a time in stages with serum-free KBM501 medium for 5% UltraGRO / KBM501 medium, (4) 0.2% UltraGRO KBM501 medium, (5) 5% UltraGRO / RPMI1640 medium, (6) 5% UltraGRO / RPMI1640 medium containing 3,000 IU / mL 11-2, (7) PPP (Platelet-pour Plasma) isolated from peripheral blood collected from a healthy human volunteer ※6 , (8) peripheral blood (PB) collected from a healthy human volunteer. After each group was left to stand for about 5 minutes, antibody staining and measurement were performed according to the procedure described in C), and analysis was performed on the presence or absence of binding of GAIA-102 and moximilomab at CD16low and CD16high in the CD56+ and CD3- cell population.

[0192] ※6: Supernatant obtained by centrifuging peripheral blood at 2000 x g for 15 minutes at room temperature (brake off)

[0193] The results are shown in Figure 4Regardless of the type of culture solution, the antibody dissociated from GAIA-102 in the presence of UG or blood. It was found that GAIA-102 could not hold the antibody by CD16 in human blood.

[0194] [Experiment 5: Effect of IgG]

[0195] According to the procedure described in Experiment 2, GAIA-102 and 100 pg / mL mogamulizumab were also reacted at room temperature for 1 hour. After washing with PBS 3 times, they were resuspended in (1) serum-free KBM501 medium containing 1 mg / mL trastuzumab (Herceptin (注册商标) UltraGRO / KBM501 medium, (3) 5% human AB serum / KBM501 medium, (4) serum-free KBM501 medium, (5) PBS. After leaving each group for about 5 minutes, the procedure described in C) was followed to perform antibody staining, measurement, and analysis of the presence or absence of binding of GAIA-102 to mogamulizumab in CD16lowand CD16highin the cell population showing CD56+and CD3-.

[0196] The results are shown in Figure 5 . It was found that the antibody drug bound to NK cells dissociated due to competition with other IgG.

[0197] [Example 1: Production of a prototype]

[0198] A protein having a region that binds to the antigen NKp46 on the NK cell membrane and a region that binds to IgG was designed, and an attempt was made to anchor the antibody drug on the cell. In more detail, as the region that binds to NKp46, the anti-human NKp46 scFv described in WO2017 / 114694 (arrangement number: 121 in the document) was used. In addition, as the region that binds to IgG, 373-297 aa in the sequence of protein G (https: / / www.uniprot.org / uniprot / P19909) was used.

[0199] The fusion protein was commissioned to KAICO Co., Ltd. 819-0388, 4-1, Kudai-shinmachi, Nishi-ku, Fukuoka-shi, Fukuoka Prefecture, Science and Technology Alliance Exchange Center 217), and was produced by using silkworm recombinant protein expression technology.

[0200] The amino acid sequence of the designed protein (385 amino acids in length) is shown in Figure 6 .

[0201] [Example 2: Anchoring of antibody drug on cell]

[0202] GAIA-102 obtained by the steps described in the culturing method of high-activity NK cells, the recovery method was anchored by the following method using the purified prototype substance (pG2-NKp46) as an anchor.

[0203] Using a low-adsorption 96-well plate (IWAKI, 4870-800SP), GAIA-102 (1 x 10 6 After centrifugation (500 x g, 5 minutes), the supernatant was removed and suspended in 25 μL of PBS containing 350 μg / mL of the prototype substance. After standing at room temperature for 1 hour, it was washed once with PBS and replaced with 25 μL of PBS containing 1 μg / mL of Herceptin, and further stood at room temperature for 1 hour. Then, it was washed once with PBS and subjected to antibody staining and measurement according to the steps described in C) to analyze the presence or absence of Herceptin binding.

[0204] Using a low-adsorption 96-well plate, Herceptin was added to 25 μL of PBS containing 350 μg / mL of the prototype substance so as to be 1 μg / mL, and stood at room temperature for 1 hour. GAIA-102 (1 x 10 6 After centrifugation, the supernatant was removed and the obtained cells were suspended in the prototype substance + Herceptin solution reacted for 1 hour. Further, it was stood at room temperature for 1 hour, washed once with PBS, and subjected to antibody staining and measurement according to the steps described in C) to analyze the presence or absence of Herceptin binding.

[0205] GAIA-102 and PBS were reacted for 1 hour, and subjected to antibody measurement according to the steps described in C) as controls of the above two groups.

[0206] The results are shown in Figure 7 It was confirmed that the prototype substance could be anchored. It was known that the prototype substance could be anchored regardless of the order of mixing with the antibody or GAIA-102.

[0207] [Example 3: Effect on various antibody drugs]

[0208] GAIA-102 (1 x 10 5 cells were suspended in 100 μL of 5% UltraGRO / KBM501 medium containing 13.3 μg / mL of the prototype substance, and stood at room temperature for 1 hour. After 1 hour, it was washed once with PBS and suspended in PBS containing 1 μg / mL of each of the following various antibody drugs: cetuximab (Erbitux (注册商标)Intravenous injection, Merck BioPharma), Herceptin, Poteligeo, Rituxan (Rituximab, Genentech), Adcetris (Brentuximab vedotin, Seattle Genetics), Darzalex (Daratumumab, Janssen Biotech), Keytruda (Pembrolizumab, Merck), Opdivo (Nivolumab, Bristol-Myers Squibb), Imfinzi (Durvalumab, AstraZeneca), Tecentriq (Atezolizumab, Genentech), Poteligeo (Denileukin diftitox, Amgen), Y-mAbs (Catumaxomab, Amgen), Mylotarg (Gemtuzumab ozogamicin, Pfizer), Kadcyla (Ado-trastuzumab emtansine, Genentech), Adcetris (Brentuximab vedotin, Seattle Genetics), Ado-trastuzumab emtansine (Kadcyla, Genentech), Daratumumab (Darzalex, Janssen Biotech), Pembrolizumab (Keytruda, Merck), Nivolumab (Opdivo, Bristol-Myers Squibb), Atezolizumab (Tecentriq, Genentech), Denileukin diftitox (Poteligeo, Amgen), Catumaxomab (Y-mAbs, Amgen), Gemtuzumab ozogamicin (Mylotarg, Pfizer), and the like. (注册商标) Intravenous injection, Merck BioPharma), Herceptin, Poteligeo, Rituxan (Rituximab, Genentech), Adcetris (Brentuximab vedotin, Seattle Genetics), Darzalex (Daratumumab, Janssen Biotech), Keytruda (Pembrolizumab, Merck), Opdivo (Nivolumab, Bristol-Myers Squibb), Imfinzi (Durvalumab, AstraZeneca), Tecentriq (Atezolizumab, Genentech), Poteligeo (Denileukin diftitox, Amgen), Y-mAbs (Catumaxomab, Amgen), Mylotarg (Gemtuzumab ozogamicin, Pfizer), Kadcyla (Ado-trastuzumab emtansine, Genentech), Adcetris (Brentuximab vedotin, Seattle Genetics), Ado-trastuzumab emtansine (Kadcyla, Genentech), Daratumumab (Darzalex, Janssen Biotech), Pembrolizumab (Keytruda, Merck), Nivolumab (Opdivo, Bristol-Myers Squibb), Atezolizumab (Tecentriq, Genentech), Denileukin diftitox (Poteligeo, Amgen), Catumaxomab (Y-mAbs, Amgen), Gemtuzumab ozogamicin (Mylotarg, Pfizer), and the like.

[0209] Results are shown in Figure 8 It was found that the binding of the cells to the antibodies was stable by the anchoring with the prototype substance regardless of the antibody drugs used.

[0210] Sequence Listing Free Text

[0211] SEQ ID NO: 1 Nucleotide sequence, pG / Fc-NKp46 / scFv

[0212] SEQ ID NO: 2 Amino acid sequence, pG / Fc-NKp46 / scFv

[0213] SEQ ID NOs: 3-12 and 32-42 Regions capable of binding to NK cell surface proteins

[0214] SEQ ID Nos: 13-31 WO2016 / 186206, SEQ ID NOs: 1-17, 36, and 37 SEQUENCE LISTING <110> GAIABIOPHARMA CO., LTD. <120> Method for stabilizing the binding of NK cells to antibodies and use thereof <130> F21618K-WO <150> JP2020-113083 <151> 2020-06-30 <160> 42 <170> PatentIn version 3.5 <210> 1 <211> 1293 <212> DNA <213> Artificial Sequence <220> <223> pG / Fc-NKp46 / scFv <220> <221> 30K signal peptide-coding region <222> (1)..(57) <220> <221> Protein G-coding region <222> (58)..(222) <220> <221> (G4S)3 linker-coding region <222> (433)..(477) <220> <221> scFv(NKp46)-coding region <222> (478)..(1212) <220> <221> TEV protease-coding region <222> (1213)..(1233) <220> <221> His tag-coding region <222> (1234)..(1251) <220> <221> Strep tag II-coding region <222> (1252)..(1275) <400> 1 atgcggctca cactattcgc tttcgtactc gctgtgtgtg ccctcgcaag caacgctacg 60 tacaaattag ttataaacgg taaaacgctg aaaggtgaga ccactacaga agccgttgac 120 gctgctacgg cggaaaaggt attcaaacag tatgcaaacg ataacggcgt tgacggtgag 180 tggacctacg acgatgcgac aaaaaccttt acagttactg aaaagcctga ggtcatcgat 240 gcctcggagc tgacaccggc ggtgacaacg tataagttgg tcataaatgg gaagacactg 300 aagggcgaga ccaccactaa agctgtggac gcggagacgg ccgaaaaggc attcaaacaa 360 tacgctaatg ataatggagt tgatggtgtg tggacgtatg acgacgcaac gaaaactttt 420 actgtcacgg aagggggtgg ggggtcagga ggtggaggca gtgggggagg gggttcgtcc 480 acaggatctg aagtccaatt gcagcaatcg ggccctgagc tcgtcaagcc aggcgcaagt 540 gttaaaattt cgtgtaagac tagcggttat acctttaccg agtatacaat gcattgggta 600 aagcaaagcc atggcaagtc cctggaatgg atcggaggaa tatctccgaa catcggtggc 660 accagctata atcaaaagtt taaagggaag gcgaccctaa cggtggacaa gagttcttct 720 accgcctaca tggagctccg cagcctaacg agtgaagatt ctgccgtgta ctattgtgcg 780 agacgtggtg ggtcctttga ctattggggg cagggtacaa cactgactgt ttcgtctgtc 840 gaaggtggtt ctggcggcag tgggggctcg gggggttcag gtggggtgga cgacattgtg 900 atgacccagt ctcctgcgac attaagtgta acgccggggg atcgtgtgtc cctgtcttgt 960 cgtgcctcac aatctattag tgattacctg cactggtacc aacagaagtc ccatgagagt 1020 ccacgcctat taatcaaata cgcctcgcag agcatctcag gcattccgtc caggttcagc 1080 gggtccggaa gtgggtcgga ctttacatta agcattaact cagttgaacc agaggacgta 1140< ggagtttact actgccaaaa tggccattca ttccccctaa ctttcggtgc gggtacgaaa 1200 [[ID=,6]]ctagaattga aagagaatct ttatttccag ggccaccatc accaccatca ctggtctcat 1260 ccacaatttg agaagcacca tcatcatcac cac 1293 <210> 2 <211> 431 <212> PRT[[ID=,15]] <213> Artificial Sequence[[ID=,17]] <220> <223> Synthetic construct <400> 2 Met Arg Leu Thr Leu Phe Ala Phe Val Leu Ala Val Cys Ala Leu Ala 1 5 10 15 Ser Asn Ala Thr Tyr Lys Leu Val Ile Asn Gly Lys Thr Leu Lys Gly 20 25 30<, Glu Thr Thr Thr Glu Ala Val Asp Ala Ala Thr Ala Glu Lys Val Phe 35 40 45 Lys Gln Tyr Ala Asn Asp Asn Gly Val Asp Gly Glu Trp Thr Tyr Asp 50 55 60 It should be noted that there seems to be a formatting issue in the original text with some tags having incorrect capitalization or punctuation in the translation above. You may want to double-check the original text's formatting for accuracy.Asp Ala Thr Lys Thr Phe Thr Val Thr Glu Lys Pro Glu Val Ile Asp 65 70 75 80 Ala Ser Glu Leu Thr Pro Ala Val Thr Thr Tyr Lys Leu Val Ile Asn 85 90 95 Gly Lys Thr Leu Lys Gly Glu Thr Thr Thr Lys Ala Val Asp Ala Glu 100 105 110 Thr Ala Glu Lys Ala Phe Lys Gln Tyr Ala Asn Asp Asn Gly Val Asp 115 120 125 Gly Val Trp Thr Tyr Asp Asp Ala Thr Lys Thr Phe Thr Val Thr Glu 130 135 140 Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Ser 145 150 155 160 Thr Gly Ser Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys 165 170 175 Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Thr Ser Gly Tyr Thr Phe 180 185 190 Thr Glu Tyr Thr Met His Trp Val Lys Gln Ser His Gly Lys Ser Leu 195 200 205 Glu Trp Ile Gly Gly Ile Ser Pro Asn Ile Gly Gly Thr Ser Tyr Asn 210 215 220 Gln Lys Phe Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser 225 230 235 240 Thr Ala Tyr Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Ser Ala Val 245 250 255 Tyr Tyr Cys Ala Arg Arg Gly Gly Ser Phe Asp Tyr Trp Gly Gln Gly 260 265 270 Thr Thr Leu Thr Val Ser Ser Val Glu Gly Gly Ser Gly Gly Ser Gly 275 280 285 Gly Ser Gly Gly Ser Gly Gly Val Asp Asp Ile Val Met Thr Gln Ser 290 295 300 Pro Ala Thr Leu Ser Val Thr Pro Gly Asp Arg Val Ser Leu Ser Cys 305 310 315 320 Arg Ala Ser Gln Ser Ile Ser Asp Tyr Leu His Trp Tyr Gln Gln Lys 325 330 335 Ser His Glu Ser Pro Arg Leu Leu Ile Lys Tyr Ala Ser Gln Ser Ile 340 345 350 Ser Gly Ile Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Ser Asp Phe 355 360 365 Thr Leu Ser Ile Asn Ser Val Glu Pro Glu Asp Val Gly Val Tyr Tyr 370 375 380 Cys Gin Asn Gly His Ser Phe Pro Leu Thr Phe Gly Ala Gly Thr Lys 385 390 395 400 Leu Glu Leu Lys Glu Asn Leu Tyr Phe Gin Gly His His His His His 405 410 415 His Trp Ser His Pro Gin Phe Glu Lys His His His His His His 420 425 430 <210> 3 <211> 238 <212> PRT <213> Homo sapiens <400> 3 Asp Leu Lys Val Glu Met Met Ala Gly Gly Thr Gin He Thr Pro Leu 1 5 10 15 Asn Asp Asn Val Thr He Phe Cys Asn He Phe Tyr Ser Gin Pro Leu 20 25 30 Asn He Thr Ser Met Gly He Thr Trp Phe Trp Lys Ser Leu Thr Phe 35 40 45 Asp Lys Glu Val Lys Val Phe Glu Phe Phe Gly Asp His Gin Glu Ala 50 55 60 Phe Arg Pro Gly Ala He Val Ser Pro Trp Arg Leu Lys Ser Gly Asp 65 70 75 80 Ala Ser Leu Arg Leu Pro Gly He Gin Leu Glu Glu Ala Gly Glu Tyr 85 90 95 Arg Cys Glu Val Val Val Thr Pro Leu Lys Ala Gln Gly Thr Val Gln 100 105 110 Leu Glu Val Val Ala Ser Pro Ala Ser Arg Leu Leu Leu Asp Gln Val 115 120 125 Gly Met Lys Glu Asn Glu Asp Lys Tyr Met Cys Glu Ser Ser Gly Phe 130 135 140 Tyr Pro Glu Ala Ile Asn Ile Thr Trp Glu Lys Gln Thr Gln Lys Phe 145 150 155 160 Pro His Pro Ile Glu Ile Ser Glu Asp Val Ile Thr Gly Pro Thr Ile 165 170 175 Lys Asn Met Asp Gly Thr Phe Asn Val Thr Ser Cys Leu Lys Leu Asn 180 185 190 Ser Ser Gln Glu Asp Pro Gly Thr Val Tyr Gln Cys Val Val Arg His 195 200 205 Ala Ser Leu His Thr Pro Leu Arg Ser Asn Phe Thr Leu Thr Ala Ala 210 215 220 Arg His Ser Leu Ser Glu Thr Glu Lys Thr Asp Asn Phe Ser 225 230 235 <210> 4 <211> 284 <212> PRT <213> Homo sapiens <400> 4 Glu Pro His Ser Leu Arg Tyr Asn Leu Thr Val Leu Ser Trp Asp Gly 1 5 10 15 Ser Val Gln Ser Gly Phe Leu Thr Glu Val His Leu Asp Gly Gln Pro 20 25 30 Phe Leu Arg Cys Asp Arg Gln Lys Cys Arg Ala Lys Pro Gln Gly Gln 35 40 45 Trp Ala Glu Asp Val Leu Gly Asn Lys Thr Trp Asp Arg Glu Thr Arg 50 55 60 Asp Leu Thr Gly Asn Gly Lys Asp Leu Arg Met Thr Leu Ala His Ile 65 70 75 80 Lys Asp Gln Lys Glu Gly Leu His Ser Leu Gln Glu Ile Arg Val Cys 85 90 95 Glu Ile His Glu Asp Asn Ser Thr Arg Ser Ser Gln His Phe Tyr Tyr 100 105 110 Asp Gly Glu Leu Phe Leu Ser Gln Asn Leu Glu Thr Lys Glu Trp Thr 115 120 125 Met Pro Gln Ser Ser Arg Ala Gln Thr Leu Ala Met Asn Val Arg Asn 130 135 140 Phe Leu Lys Glu Asp Ala Met Lys Thr Lys Thr His Tyr His Ala Met 145 150 155 160 His Ala Asp Cys Leu Gln Glu Leu Arg Arg Tyr Leu Lys Ser Gly Val 165 170 175 Val Leu Arg Arg Thr Val Pro Pro Met Val Asn Val Thr Arg Ser Glu 180 185 190 Ala Ser Glu Gly Asn Ile Thr Val Thr Cys Arg Ala Ser Gly Phe Tyr 195 200 205 Pro Trp Asn Ile Thr Leu Ser Trp Arg Gln Asp Gly Val Ser Leu Ser 210 215 220 His Asp Thr Gln Gln Trp Gly Asp Val Leu Pro Asp Gly Asn Gly Thr 225 230 235 240 Tyr Gln Thr Trp Val Ala Thr Arg Ile Cys Gln Gly Glu Glu Gln Arg 245 250 255 Phe Thr Cys Tyr Met Glu His Ser Gly Asn His Ser Thr His Pro Val 260 265 270 Pro Ser Gly Lys Val Leu Val Leu Gln Ser His Trp 275 280 <210> 5 <211> 287 <212> PRT <213> Homo sapiens <400> 5 Ala Glu Pro His Ser Leu Arg Tyr Asn Leu Met Val Leu Ser Gin Asp 1 5 10 15 Gly Ser Val Gin Ser Gly Phe Leu Ala Glu Gly His Leu Asp Gly Gin 20 25 30 Pro Phe Leu Arg Tyr Asp Arg Gin Lys Arg Arg Ala Lys Pro Gin Gly 35 40 45 Gln Trp Ala Glu Asn Val Leu Gly Ala Lys Thr Trp Asp Thr Glu Thr 50 55 60 Glu Asp Leu Thr Glu Asn Gly Gin Asp Leu Arg Arg Thr Leu Thr His 65 70 75 80 Ile Lys Asp Gin Lys Gly Gly Leu His Ser Leu Gin Glu Ile Arg Val 85 90 95 Cys Glu Ile His Glu Asp Ser Ser Thr Arg Gly Ser Arg His Phe Tyr 100 105 110 Tyr Asp Gly Glu Leu Phe Leu Ser Gin Asn Leu Glu Thr Gin Glu Ser 115 120 125 Thr Val Pro Gin Ser Ser Arg Ala Gin Thr Leu Ala Met Asn Val Thr 130 135 140 Asn Phe Trp Lys Glu Asp Ala Met Lys Thr Lys Thr His Tyr Arg Ala 145 150 155 160 Met Gin Ala Asp Cys Leu Gin Lys Leu Gin Arg Tyr Leu Lys Ser Gly 165 170 175 Val Ala He Arg Arg Thr Val Pro Pro Met Val Asn Val Thr Cys Ser 180 185 190 Glu Val Ser Glu Gly Asn He Thr Val Thr Cys Arg Ala Ser Ser Phe 195 200 205 Tyr Pro Arg Asn He Thr Leu Thr Trp Arg Gin Asp Gly Val Ser Leu 210 215 220 Ser His Asn Thr Gin Gin Trp Gly Asp Val Leu Pro Asp Gly Asn Gly 225 230 235 240 Thr Tyr Gin Thr Trp Val Ala Thr Arg He Arg Gin Gly Glu Glu Gin 245 250 255 Arg Phe Thr Cys Tyr Met Glu His Ser Gly Asn His Gly Thr His Pro 260 265 270 Val Pro Ser Gly Lys Ala Leu Val Leu Gin Ser Gin Arg Thr Asp 275 280 285 <210> 6 <211> 175 <212> PRT <213> Homo sapiens <400> 6 Ile Thr Cys Pro Pro Pro Met Ser Val Glu His Ala Asp He Trp Val 1 5 10 15 Lys Ser Tyr Ser Leu Tyr Ser Arg Glu Arg Tyr Ile Cys Asn Ser Gly 20 25 30 Phe Lys Arg Lys Ala Gly Thr Ser Ser Leu Thr Glu Cys Val Leu Asn 35 40 45 Lys Ala Thr Asn Val Ala His Trp Thr Thr Pro Ser Leu Lys Cys Ile 50 55 60 Arg Asp Pro Ala Leu Val His Gln Arg Pro Ala Pro Pro Ser Thr Val 65 70 75 80 Thr Thr Ala Gly Val Thr Pro Gln Pro Glu Ser Leu Ser Pro Ser Gly 85 90 95 Lys Glu Pro Ala Ala Ser Ser Pro Ser Ser Asn Asn Thr Ala Ala Thr 100 105 110 Thr Ala Ala Ile Val Pro Gly Ser Gln Leu Met Pro Ser Lys Ser Pro 115 120 125 Ser Thr Gly Thr Thr Glu Ile Ser Ser His Glu Ser Ser His Gly Thr 130 135 140 Pro Ser Gln Thr Thr Ala Lys Asn Trp Glu Leu Thr Ala Ser Ala Ser 145 150 155 160 His Gln Pro Pro Gly Val Tyr Pro Gln Gly His Ser Asp Thr Thr 165 170 175 <210> 7 <211> 214 <212> PRT <213> Homo sapiens <400> 7 Ala Val Asn Gly Thr Ser Gin Phe Thr Cys Phe Tyr Asn Ser Arg Ala 1 5 10 15 Asn Ile Ser Cys Val Trp Ser Gin Asp Gly Ala Leu Gin Asp Thr Ser 20 25 30 Cys Gin Val His Ala Trp Pro Asp Arg Arg Arg Trp Asn Gin Thr Cys 35 40 45 Glu Leu Leu Pro Val Ser Gin Ala Ser Trp Ala Cys Asn Leu Ile Leu 50 55 60 Gly Ala Pro Asp Ser Gin Lys Leu Thr Thr Val Asp Ile Val Thr Leu 65 70 75 80 Arg Val Leu Cys Arg Glu Gly Val Arg Trp Arg Val Met Ala Ile Gin 85 90 95 Asp Phe Lys Pro Phe Glu Asn Leu Arg Leu Met Ala Pro Ile Ser Leu 100 105 110 Gln Val Val His Val Glu Thr His Arg Cys Asn Ile Ser Trp Glu Ile 115 120 125 Ser Gin Ala Ser His Tyr Phe Glu Arg His Leu Glu Phe Glu Ala Arg 130 135 140 Thr Leu Ser Pro Gly His Thr Trp Glu Glu Ala Pro Leu Leu Thr Leu 145 150 155 160 Lys Gln Lys Gln Glu Trp Ile Cys Leu Glu Thr Leu Thr Pro Asp Thr 165 170 175 Gln Tyr Glu Phe Gln Val Arg Val Lys Pro Leu Gln Gly Glu Phe Thr 180 185 190 Thr Trp Ser Pro Trp Ser Gln Pro Leu Ala Phe Arg Thr Lys Pro Ala 195 200 205 Ala Leu Gly Lys Asp Thr 210 <210> 8 [[ID=||ID=24]]<211> 284 <||ID=212> PRT <213> Homo sapiens <400> 8 Gly Ser His Ser Leu Arg Tyr Phe Ser Thr Ala Val Ser Arg Pro Gly 1 5 10 15 Arg Gly Glu Pro Arg Tyr Ile Ala Val Glu Tyr Val Asp Asp Thr Gln 20 25 30 Phe Leu Arg Phe Asp Ser Asp Ala Ala Ile Pro Arg Met Glu Pro Arg 35 40 ||ID=45 Glu Pro Trp Val Glu Gln Glu Gly Pro Gln Tyr Trp Glu Trp Thr Thr 50 55 60 It seems there are some formatting or unclear parts in the original text (e.g., the double "||ID=" in the middle). Please check and clarify if needed for a more accurate translation.Gly Tyr Ala Lys Ala Asn Ala Gin Thr Asp Arg Val Ala Leu Arg Asn 65 70 75 80 Leu Leu Arg Arg Tyr Asn Gin Ser Glu Ala Gly Ser His Thr Leu Gin 85 90 95 Gly Met Asn Gly Cys Asp Met Gly Pro Asp Gly Arg Leu Leu Arg Gly 100 105 110 Tyr His Gin His Ala Tyr Asp Gly Lys Asp Tyr He Ser Leu Asn Glu 115 120 125 Asp Leu Arg Ser Trp Thr Ala Ala Asp Thr Val Ala Gin He Thr Gin 130 135 140 Arg Phe Tyr Glu Ala Glu Glu Tyr Ala Glu Glu Phe Arg Thr Tyr Leu 145 150 155 160 Glu Gly Glu Cys Leu Glu Leu Leu Arg Arg Tyr Leu Glu Asn Gly Lys 165 170 175 Glu Thr Leu Gin Arg Ala Asp Pro Pro Lys Ala His Val Ala His His 180 185 190 Pro He Ser Asp His Glu Ala Thr Leu Arg Cys Trp Ala Leu Gly Phe 195 200 205 Tyr Pro Ala Glu He Thr Leu Thr Trp Gin Arg Asp Gly Glu Glu Gin 210 215 220 Thr Gin Asp Thr Glu Leu Val Glu Thr Arg Pro Ala Gly Asp Gly Thr 225 230 235 240 Phe Gin Lys Trp Ala Ala Val Val Val Pro Pro Gly Glu Glu Gin Arg 245 250 255 Tyr Thr Cys His Val Gin His Glu Gly Leu Pro Gin Pro Leu lie Leu 260 265 270 Arg Trp Glu Gin Ser Pro Gin Pro Thr lie Pro lie 275 280 <210> 9 <211> 285 <212> PRT <213> Homo sapiens <400> 9 Gly Ser His Ser Met Arg Tyr Phe Tyr Thr Ser Val Ser Arg Pro Gly 1 5 10 15 Arg Gly Glu Pro Arg Phe lie Ser Val Gly Tyr Val Asp Asp Thr Gin 20 25 30 Phe Val Arg Phe Asp Ser Asp Ala Ala Ser Pro Arg Glu Glu Pro Arg 35 40 45 Ala Pro Trp lie Glu Gin Glu Gly Pro Glu Tyr Trp Asp Arg Asn Thr 50 55 60 Gln lie Tyr Lys Ala Gin Ala Gin Thr Asp Arg Glu Ser Leu Arg Asn 65 70 75 80 Leu Arg Gly Tyr Tyr Asn Gln Ser Glu Ala Gly Ser His Thr Leu Gln 85 90 95 Ser Met Tyr Gly Cys Asp Val Gly Pro Asp Gly Arg Leu Leu Arg Gly 100 105 110 His Asp Gln Tyr Ala Tyr Asp Gly Lys Asp Tyr Ile Ala Leu Asn Glu 115 120 125 Asp Leu Arg Ser Trp Thr Ala Ala Asp Thr Ala Ala Gln Ile Thr Gln 130 135 140 Arg Lys Trp Glu Ala Ala Arg Glu Ala Glu Gln Arg Arg Ala Tyr Leu 145 150 155 160 Glu Gly Glu Cys Val Glu Trp Leu Arg Arg Tyr Leu Glu Asn Gly Lys 165 170 175 Asp Lys Leu Glu Arg Ala Asp Pro Pro Lys Thr His Val Thr His His 180 185 190 Pro Ile Ser Asp His Glu Ala Thr Leu Arg Cys Trp Ala Leu Gly Phe 195 200 205 Tyr Pro Ala Glu Ile Thr Leu Thr Trp Gln Arg Asp Gly Glu Asp Gln 210 215 220 Thr Gln Asp Thr Glu Leu Val Glu Thr Arg Pro Ala Gly Asp Arg Thr 225 230 235 240 Phe Gin Lys Trp Ala Ala Val Val Val Pro Ser Gly Glu Glu Gin Arg 245 250 255 Tyr Thr Cys His Val Gin His Glu Gly Leu Pro Lys Pro Leu Thr Leu 260 265 270 Arg Trp Glu Pro Ser Ser Gin Ser Thr Val Pro Ile Val 275 280 285 <210> 10 <211> 284 <212> PRT <213> Homo sapiens <400> 10 Gly Ser His Ser Leu Lys Tyr Phe His Thr Ser Val Ser Arg Pro Gly 1 5 10 15 Arg Gly Glu Pro Arg Phe Ile Ser Val Gly Tyr Val Asp Asp Thr Gin 20 25 30 Phe Val Arg Phe Asp Asn Asp Ala Ala Ser Pro Arg Met Val Pro Arg 35 40 45 Ala Pro Trp Met Glu Gin Glu Gly Ser Glu Tyr Trp Asp Arg Glu Thr 50 55 60 Arg Ser Ala Arg Asp Thr Ala Gin Ile Phe Arg Val Asn Leu Arg Thr 65 70 75 80 Leu Arg Gly Tyr Tyr Asn Gin Ser Glu Ala Gly Ser His Thr Leu Gin 85 90 95 Trp Met His Gly Cys Glu Leu Gly Pro Asp Gly Arg Phe Leu Arg Gly 100 105 110 Tyr Glu Gin Phe Ala Tyr Asp Gly Lys Asp Tyr Leu Thr Leu Asn Glu 115 120 125 Asp Leu Arg Ser Trp Thr Ala Val Asp Thr Ala Ala Gin He Ser Glu 130 135 140 Gln Lys Ser Asn Asp Ala Ser Glu Ala Glu His Gin Arg Ala Tyr Leu 145 150 155 160 Glu Asp Thr Cys Val Glu Trp Leu His Lys Tyr Leu Glu Lys Gly Lys 165 170 175 Glu Thr Leu Leu His Leu Glu Pro Pro Lys Thr His Val Thr His His 180 185 190 Pro He Ser Asp His Glu Ala Thr Leu Arg Cys Trp Ala Leu Gly Phe 195 200 205 Tyr Pro Ala Glu He Thr Leu Thr Trp Gin Gin Asp Gly Glu Gly His 210 215 220 Thr Gin Asp Thr Glu Leu Val Glu Thr Arg Pro Ala Gly Asp Gly Thr 225 230 235 240 Phe Gin Lys Trp Ala Ala Val Val Val Pro Ser Gly Glu Glu Gin Arg 245 250 255 Tyr Thr Cys His Val Gin His Glu Gly Leu Pro Glu Pro Val Thr Leu 260 265 270 Arg Trp Lys Pro Ala Ser Gin Pro Thr He Pro He 275 280 <210> 11 <211> 329 <212> PRT <213> Homo sapiens <400> 11 Gln Asp Val Arg Val Gin Val Leu Pro Glu Val Arg Gly Gin Leu Gly 1 5 10 15 Gly Thr Val Glu Leu Pro Cys His Leu Leu Pro Pro Val Pro Gly Leu 20 25 30 Tyr He Ser Leu Val Thr Trp Gin Arg Pro Asp Ala Pro Ala Asn His 35 40 45 Gln Asn Val Ala Ala Phe His Pro Lys Met Gly Pro Ser Phe Pro Ser 50 55 60 Pro Lys Pro Gly Ser Glu Arg Leu Ser Phe Val Ser Ala Lys Gin Ser 65 70 75 80 Thr Gly Gin Asp Thr Glu Ala Glu Leu Gin Asp Ala Thr Leu Ala Leu 85 90 95 His Gly Leu Thr Val Glu Asp Glu Gly Asn Tyr Thr Cys Glu Phe Ala 100 105 110 Thr Phe Pro Lys Gly Ser Val Arg Gly Met Thr Trp Leu Arg Val Ile 115 120 125 Ala Lys Pro Lys Asn Gln Ala Glu Ala Gln Lys Val Thr Phe Ser Gln 130 135 140 Asp Pro Thr Thr Val Ala Leu Cys Ile Ser Lys Glu Gly Arg Pro Pro 145 150 155 160 Ala Arg Ile Ser Trp Leu Ser Ser Leu Asp Trp Glu Ala Lys Glu Thr 165 170 175 Gln Val Ser Gly Thr Leu Ala Gly Thr Val Thr Val Thr Ser Arg Phe 180 185 190 Thr Leu Val Pro Ser Gly Arg Ala Asp Gly Val Thr Val Thr Cys Lys 195 200 205 Val Glu His Glu Ser Phe Glu Glu Pro Ala Leu Ile Pro Val Thr Leu 210 215 220 Ser Val Arg Tyr Pro Pro Glu Val Ser Ile Ser Gly Tyr Asp Asp Asn 225 230 235 240 Trp Tyr Leu Gly Arg Thr Asp Ala Thr Leu Ser Cys Asp Val Arg Ser 245 250 255 Asn Pro Glu Pro Thr Gly Tyr Asp Trp Ser Thr Thr Ser Gly Thr Phe 260 265 270 Pro Thr Ser Ala Val Ala Gln Gly Ser Gln Leu Val Ile His Ala Val 275 280 285 Asp Ser Leu Phe Asn Thr Thr Phe Val Cys Thr Val Thr Asn Ala Val 290 295 300 Gly Met Gly Arg Ala Glu Gln Val Ile Phe Val Arg Glu Thr Pro Asn 305 310 315 320 Thr Ala Gly Ala Gly Ala Thr Gly Gly 325 <210> 12 <211> 323 <212> PRT <213> Homo sapiens <400> 12 Trp Pro Pro Pro Gly Thr Gly Asp Val Val Val Gln Ala Pro Thr Gln 1 5 10 15 Val Pro Gly Phe Leu Gly Asp Ser Val Thr Leu Pro Cys Tyr Leu Gln 20 25 30 Val Pro Asn Met Glu Val Thr His Val Ser Gln Leu Thr Trp Ala Arg 35 40 45 His Gly Glu Ser Gly Ser Met Ala Val Phe His Gln Thr Gln Gly Pro 50 55 60 Ser Tyr Ser Glu Ser Lys Arg Leu Glu Phe Val Ala Ala Arg Leu Gly 65 70 75 80 Ala Glu Leu Arg Asn Ala Ser Leu Arg Met Phe Gly Leu Arg Val Glu 85 90 95 Asp Glu Gly Asn Tyr Thr Cys Leu Phe Val Thr Phe Pro Gln Gly Ser 100 105 110 Arg Ser Val Asp Ile Trp Leu Arg Val Leu Ala Lys Pro Gln Asn Thr 115 120 125 Ala Glu Val Gln Lys Val Gln Leu Thr Gly Glu Pro Val Pro Met Ala 130 135 140 Arg Cys Val Ser Thr Gly Gly Arg Pro Pro Ala Gln Ile Thr Trp His 145 150 155 160 Ser Asp Leu Gly Gly Met Pro Asn Thr Ser Gln Val Pro Gly Phe Leu 165 170 175 Ser Gly Thr Val Thr Val Thr Ser Leu Trp Ile Leu Val Pro Ser Ser 180 185 190 Gln Val Asp Gly Lys Asn Val Thr Cys Lys Val Glu His Glu Ser Phe 195 200 205 Glu Lys Pro Gln Leu Leu Thr Val Asn Leu Thr Val Tyr Tyr Pro Pro 210 215 220 Glu Val Ser Ile Ser Gly Tyr Asp Asn Asn Trp Tyr Leu Gly Gln Asn 225 230 235 240 Glu Ala Thr Leu Thr Cys Asp Ala Arg Ser Asn Pro Glu Pro Thr Gly 245 250 255 Tyr Asn Trp Ser Thr Thr Met Gly Pro Leu Pro Pro Phe Ala Val Ala 260 265 270 Gln Gly Ala Gln Leu Leu Ile Arg Pro Val Asp Lys Pro Ile Asn Thr 275 280 285 Thr Leu Ile Cys Asn Val Thr Asn Ala Leu Gly Ala Arg Gln Ala Glu 290 295 300 Leu Thr Val Gln Val Lys Glu Gly Pro Pro Ser Glu His Ser Gly Ile 305 310 315 320 Ser Arg Asn <210> 13 <211> 13 <212> PRT <213> Artificial Sequence <220> <221> misc_feature <222> (6)..(6) <223> Xaa is Lys, Cys, Asp, Glu, 2-amino octanedioic acid, or diaminopropionic acid <400> 13 Asp Cys Ala Tyr His Xaa Gly Glu Leu Val Trp Cys Thr 1 5 10 <210> 14 <211> 17 <212> PRT <213> Artificial Sequence <220> <221> misc_feature <222> (8)..(8) <223> Xaa is Lys, Cys, Asp, Glu, 2-amino octanedioic acid, or diaminopropionic acid <400> 14 Gly Pro Asp Cys Ala Tyr His Xaa Gly Glu Leu Val Trp Cys Thr Phe 1 5 10 15 His <210> 15 <211> 13 <212> PRT <213> Artificial Sequence <220> <221> misc_feature <222> (6)..(6) <223> Xaa is Lys, Cys, Asp, Glu, 2-amino octanedioic acid, or diaminopropionic acid <400> 15 Arg Cys Ala Tyr His Xaa Gly Glu Leu Val Trp Cys Ser 1 5 10 <210> 16 <211> 17 <212> PRT <213> Artificial Sequence <220> <221> misc_feature <222> (8)..(8) <223> Xaa is Lys, Cys, Asp, Glu, 2-amino octanedioic acid, or diaminopropionic acid <400> 16 Gly Pro Arg Cys Ala Tyr His Xaa Gly Glu Leu Val Trp Cys Ser Phe 1 5 10 15 His <210> 17 <211> 17 <212> PRT <213> Artificial Sequence <220> <221> misc_feature <222> (8)..(8) <223> Xaa is Lys, Cys, Asp, Glu, 2-amino octanedioic acid, or diaminopropionic acid <400> 17 Ser Pro Asp Cys Ala Tyr His Xaa Gly Glu Leu Val Trp Cys Thr Phe 1 5 10 15 His <210> 18 <211> 17 <212> PRT <213> Artificial Sequence <220> <221> misc_feature <222> (8)..(8) <223> Xaa is Lys, Cys, Asp, Glu, 2-amino octanedioic acid, or diaminopropionic acid <400> 18 Gly Asp Asp Cys Ala Tyr His Xaa Gly Glu Leu Val Trp Cys Thr Phe 1 5 10 15 His <210> 19 <211> 17 <212> PRT <213> Artificial Sequence <220> <221> misc_feature <222> (8)..(8) <223> Xaa is Lys, Cys, Asp, Glu, 2-amino octanedioic acid, or diaminopropionic acid <400> 19 Gly Pro Ser Cys Ala Tyr His Xaa Gly Glu Leu Val Trp Cys Thr Phe 1 5 10 15 His <210> 20 <211> 17 <212> PRT <213> Artificial Sequence <220> <221> misc_feature <222> (8)..(8) <223> Xaa is Lys, Cys, Asp, Glu, 2-amino octanedioic acid, or diaminopropionic acid <400> 20 Gly Pro Asp Cys Ala Tyr His Xaa Gly Glu Leu Val Trp Cys Ser Phe 1 5 10 15 His <210> 21 <211> 17 <212> PRT <213> Artificial Sequence <220> <221> misc_feature <222> (8)..(8) <223> Xaa is Lys, Cys, Asp, Glu, 2-amino octanedioic acid, or diaminopropionic acid <400> 21 Gly Pro Asp Cys Ala Tyr His Xaa Gly Glu Leu Val Trp Cys Thr His 1 5 10 15 His <210> 22 <211> 17 <212> PRT <213> Artificial Sequence <220> <221> misc_feature <222> (8)..(8) <223> Xaa is Lys, Cys, Asp, Glu, 2-amino octanedioic acid, or diaminopropionic acid <400> 22 Gly Pro Asp Cys Ala Tyr His Xaa Gly Glu Leu Val Trp Cys Thr Phe 1 5 10 15 Tyr <210> 23 <211> 17 <212> PRT <213> Artificial Sequence <220> <221> misc_feature <222> (8)..(8) <223> Xaa is Lys, Cys, Asp, Glu, 2-amino octanedioic acid, or diaminopropionic acid <400> 23 Ser Pro Asp Cys Ala Tyr His Xaa Gly Glu Leu Val Trp Cys Thr Phe 1 5 10 15 Tyr <210> 24 <211> 17 <212> PRT <213> Artificial Sequence <220> <221> misc_feature <222> (8)..(8) <223> Xaa is Lys, Cys, Asp, Glu, 2-amino octanedioic acid, or diaminopropionic acid <400> 24 Ser Asp Asp Cys Ala Tyr His Xaa Gly Glu Leu Val Trp Cys Thr Phe 1 5 10 15 Tyr <210> 25 <211> 17 <212> PRT <213> Artificial Sequence <220> <221> misc_feature <222> (8)..(8) <223> Xaa is Lys, Cys, Asp, Glu, 2-amino octanedioic acid, or diaminopropionic acid <400> 25 Arg Gly Asn Cys Ala Tyr His Xaa Gly Gln Leu Val Trp Cys Thr Tyr 1 5 10 15 His <210> 26 <211> 13 <212> PRT <213> Artificial Sequence <220> <221> misc_feature <222> (6)..(6) <223> Xaa is Lys, Cys, Asp, Glu, 2-amino octanedioic acid, or diaminopropionic acid <400> 26 Asp Cys Thr Tyr His Xaa Gly Asn Leu Val Trp Cys Thr 1 5 10 <210> 27 <211> 13 <212> PRT <213> Artificial Sequence <220> <221> misc_feature <222> (6)..(6) <223> Xaa is Lys, Cys, Asp, Glu, 2-amino octanedioic acid, or diaminopropionic acid <400> 27 Asp Cys Ala Tyr His Xaa Gly Asn Leu Val Trp Cys Thr 1 5 10 <210> 28 <211> 13 <212> PRT <213> Artificial Sequence <220> <221> misc_feature <222> (6)..(6) <223> Xaa is Lys, Cys, Asp, Glu, 2-amino octanedioic acid, or diaminopropionic acid <400> 28 Asp Cys Thr Tyr His Xaa Gly Glu Leu Val Trp Cys Thr 1 5 10 <210> 29 <211> 13 <212> PRT <213> Artificial Sequence <220> <221> misc_feature <222> (6)..(6) <223> Xaa is Lys, Cys, Asp, Glu, 2-amino octanedioic acid, or diaminopropionic acid <400> 29 Asp Cys Ala Trp His Xaa Gly Glu Leu Val Trp Cys Thr 1 5 10 <210> 30 <211> 17 <212> PRT <213> Artificial Sequence <220> <221> misc_feature <222> (2)..(2) <223> Xaa is Lys, Cys, Asp, Glu, 2-amino octanedioic acid, or diaminopropionic acid <220> <221> misc_feature <222> (8)..(8) <223> Xaa is Ala, Ser or Thr <220> <221> misc_feature <222> (16)..(16) <223> Xaa is Lys, Cys, Asp, Glu, 2-amino octanedioic acid, or diaminopropionic acid <400> 30 Gly Xaa Asp Cys Ala Tyr His Xaa Gly Glu Leu Val Trp Cys Thr Xaa 1 5 10 15 His <210> 31 <211> 19 <212> PRT <213> Artificial Sequence <220> <221> misc_feature <222> (10)..(10) <223> Xaa is Lys, Cys, Asp, Glu, 2-amino octanedioic acid, or diaminopropionic acid <400> 31 Arg Arg Gly Pro Asp Cys Ala Tyr His Xaa Gly Glu Leu Val Trp Cys 1 5 10 15 Thr Phe His <210> 32 <211> 465 <212> PRT <213> Homo sapiens <400> 32 Ser Thr Arg Ser Val Ser Ser Ser Ser Tyr Arg Arg Met Phe Gly Gly 1 5 10 15 Pro Gly Thr Ala Ser Arg Pro Ser Ser Ser Arg Ser Tyr Val Thr Thr 20 25 30 Ser Thr Arg Thr Tyr Ser Leu Gly Ser Ala Leu Arg Pro Ser Thr Ser 35 40 45 Arg Ser Leu Tyr Ala Ser Ser Pro Gly Gly Val Tyr Ala Thr Arg Ser 50 55 60 Ser Ala Val Arg Leu Arg Ser Ser Val Pro Gly Val Arg Leu Leu Gln 65 70 75 80 Asp Ser Val Asp Phe Ser Leu Ala Asp Ala Ile Asn Thr Glu Phe Lys 85 90 95 Asn Thr Arg Thr Asn Glu Lys Val Glu Leu Gln Glu Leu Asn Asp Arg 100 105 110 Phe Ala Asn Tyr Ile Asp Lys Val Arg Phe Leu Glu Gln Gln Asn Lys 115 120 125 Ile Leu Leu Ala Glu Leu Glu Gln Leu Lys Gly Gln Gly Lys Ser Arg 130 135 140 Leu Gly Asp Leu Tyr Glu Glu Glu Met Arg Glu Leu Arg Arg Gln Val 145 150 155 160 Asp Gln Leu Thr Asn Asp Lys Ala Arg Val Glu Val Glu Arg Asp Asn 165 170 175 Leu Ala Glu Asp Ile Met Arg Leu Arg Glu Lys Leu Gln Glu Glu Met 180 185 190 Leu Gln Arg Glu Glu Ala Glu Asn Thr Leu Gln Ser Phe Arg Gln Asp 195 200 205 Val Asp Asn Ala Ser Leu Ala Arg Leu Asp Leu Glu Arg Lys Val Glu 210 215 220 Ser Leu Gln Glu Glu Ile Ala Phe Leu Lys Lys Leu His Glu Glu Glu 225 230 235 240 Ile Gln Glu Leu Gln Ala Gln Ile Gln Glu Gln His Val Gln Ile Asp 245 250 255 Val Asp Val Ser Lys Pro Asp Leu Thr Ala Ala Leu Arg Asp Val Arg 260 265 270 Gln Gln Tyr Glu Ser Val Ala Ala Lys Asn Leu Gln Glu Ala Glu Glu 275 280 285 Trp Tyr Lys Ser Lys Phe Ala Asp Leu Ser Glu Ala Ala Asn Arg Asn 290 295 300 Asn Asp Ala Leu Arg Gln Ala Lys Gln Glu Ser Thr Glu Tyr Arg Arg 305 310 315 320 Gln Val Gln Ser Leu Thr Cys Glu Val Asp Ala Leu Lys Gly Thr Asn 325 330 335 Glu Ser Leu Glu Arg Gln Met Arg Glu Met Glu Glu Asn Phe Ala Val 340 345 350 Glu Ala Ala Asn Tyr Gln Asp Thr Ile Gly Arg Leu Gln Asp Glu Ile 355 360 365 Gln Asn Met Lys Glu Glu Met Ala Arg His Leu Arg Glu Tyr Gln Asp 370 375 380 Leu Leu Asn Val Lys Met Ala Leu Asp Ile Glu Ile Ala Thr Tyr Arg 385 390 395 400 Lys Leu Leu Glu Gly Glu Glu Ser Arg Ile Ser Leu Pro Leu Pro Asn 405 410 415 Phe Ser Ser Leu Asn Leu Arg Glu Thr Asn Leu Asp Ser Leu Pro Leu 420 425 430 Val Asp Thr His Ser Lys Arg Thr Leu Leu Ile Lys Thr Val Glu Thr 435 440 445 Arg Asp Gly Gln Val Ile Asn Glu Thr Ser Gln His His Asp Asp Leu 450 455 460 Glu 465 <210> 33 <211> 191 <212> PRT <213> Homo sapiens <400> 33 Gly Trp Val Asp Thr His Cys Leu Cys Tyr Asp Phe Ile Ile Thr Pro 1 5 10 15 Lys Ser Arg Pro Glu Pro Gln Trp Cys Glu Val Gln Gly Leu Val Asp 20 25 30 Glu Arg Pro Phe Leu His Tyr Asp Cys Val Asn His Lys Ala Lys Ala 35 40 45 Phe Ala Ser Leu Gly Lys Lys Val Asn Val Thr Lys Thr Trp Glu Glu 50 55 60 Gln Thr Glu Thr Leu Arg Asp Val Val Asp Phe Leu Lys Gly Gln Leu 65 70 75 80 Leu Asp Ile Gln Val Glu Asn Leu Ile Pro Ile Glu Pro Leu Thr Leu 85 90 95 Gln Ala Arg Met Ser Cys Glu His Glu Ala His Gly His Gly Arg Gly 100 105 110 Ser Trp Gln Phe Leu Phe Asn Gly Gln Lys Phe Leu Leu Phe Asp Ser 115 120 125 Asn Asn Arg Lys Trp Thr Ala Leu His Pro Gly Ala Lys Lys Met Thr 130 135 140 Glu Lys Trp Glu Lys Asn Arg Asp Val Thr Met Phe Phe Gln Lys Ile 145 150 155 160 Ser Leu Gly Asp Cys Lys Met Trp Leu Glu Glu Phe Leu Met Tyr Trp 165 170 175 Glu Gln Met Leu Asp Pro Thr Lys Pro Pro Ser Leu Ala Pro Gly 180 185 190 <210> 34 <211> 191 <212> PRT <213> Homo sapiens <400> 34 Gly Arg Ala Asp Pro His Ser Leu Cys Tyr Asp Ile Thr Val Ile Pro 1 5 10 15 Lys Phe Arg Pro Gly Pro Arg Trp Cys Ala Val Gln Gly Gln Val Asp 20 25 30 Glu Lys Thr Phe Leu His Tyr Asp Cys Gly Asn Lys Thr Val Thr Pro 35 40 45 Val Ser Pro Leu Gly Lys Lys Leu Asn Val Thr Thr Ala Trp Lys Ala 50 55 60 Gln Asn Pro Val Leu Arg Glu Val Val Asp Ile Leu Thr Glu Gln Leu 65 70 75 80 Arg Asp Ile Gln Leu Glu Asn Tyr Thr Pro Lys Glu Pro Leu Thr Leu 85 90 95 Gln Ala Arg Met Ser Cys Glu Gin Lys Ala Glu Gly His Ser Ser Gly 100 105 110 Ser Trp Gin Phe Ser Phe Asp Gly Gin He Phe Leu Leu Phe Asp Ser 115 120 125 Glu Lys Arg Met Trp Thr Thr Val His Pro Gly Ala Arg Lys Met Lys 130 135 140 Glu Lys Trp Glu Asn Asp Lys Val Val Ala Met Ser Phe His Tyr Phe 145 150 155 160 Ser Met Gly Asp Cys He Gly Trp Leu Glu Asp Phe Leu Met Gly Met 165 170 175 Asp Ser Thr Leu Glu Pro Ser Ala Gly Ala Pro Leu Ala Met Ser 180 185 190 <210> 35 <211> 188 <212> PRT <213> Homo sapiens <400> 35 Asp Ala His Ser Leu Trp Tyr Asn Phe Thr He He His Leu Pro Arg 1 5 10 15 His Gly Gin Gin Trp Cys Glu Val Gin Ser Gin Val Asp Gin Lys Asn 20 25 30 Phe Leu Ser Tyr Asp Cys Gly Ser Asp Lys Val Leu Ser Met Gly His 35 40 45 Leu Glu Glu Gln Leu Tyr Ala Thr Asp Ala Trp Gly Lys Gln Leu Glu 50 55 60 Met Leu Arg Glu Val Gly Gln Arg Leu Arg Leu Glu Leu Ala Asp Thr 65 70 75 80 Glu Leu Glu Asp Phe Thr Pro Ser Gly Pro Leu Thr Leu Gln Val Arg 85 90 95 Met Ser Cys Glu Cys Glu Ala Asp Gly Tyr Ile Arg Gly Ser Trp Gln 100 105 110 Phe Ser Phe Asp Gly Arg Lys Phe Leu Leu Phe Asp Ser Asn Asn Arg 115 120 125 Lys Trp Thr Val Val His Ala Gly Ala Arg Arg Met Lys Glu Lys Trp 130 135 140 Glu Lys Asp Ser Gly Leu Thr Thr Phe Phe Lys Met Val Ser Met Arg 145 150 155 160 Asp Cys Lys Ser Trp Leu Arg Asp Phe Leu Met His Arg Lys Lys Arg 165 170 175 Leu Glu Pro Thr Ala Pro Pro Thr Met Ala Pro Gly 180 185 <210> 36 <211> 233 <212> PRT <213> Homo sapiens <400> 36 His Ser Leu Cys Phe Asn Phe Thr lie Lys Ser Leu Ser Arg Pro Gly 1 5 10 15 Gln Pro Trp Cys Glu Ala Gln Val Phe Leu Asn Lys Asn Leu Phe Leu 20 25 30 Gln Tyr Asn Ser Asp Asn Asn Met Val Lys Pro Leu Gly Leu Leu Gly 35 40 45 Lys Lys Val Tyr Ala Thr Ser Thr Trp Gly Glu Leu Thr Gln Thr Leu 50 55 60 Gly Glu Val Gly Arg Asp Leu Arg Met Leu Leu Cys Asp lie Lys Pro 65 70 75 80 Gln lie Lys Thr Ser Asp Pro Ser Thr Leu Gln Val Glu Met Phe Cys 85 90 95 Gln Arg Glu Ala Glu Arg Cys Thr Gly Ala Ser Trp Gln Phe Ala Thr 100 105 110 Asn Gly Glu Lys Ser Leu Leu Phe Asp Ala Met Asn Met Thr Trp Thr 115 120 125 Val lie Asn His Glu Ala Ser Lys lie Lys Glu Thr Trp Lys Lys Asp 130 135 140 Arg Gly Leu Glu Lys Tyr Phe Arg Lys Leu Ser Lys Gly Asp Cys Asp 145 150 155 160 His Trp Leu Arg Glu Phe Leu Gly His Trp Glu Ala Met Pro Glu Pro 165 170 175 Thr Val Ser Pro Val Asn Ala Ser Asp Ile His Trp Ser Ser Ser Ser 180, 185, 190 Leu Pro Asp Arg Trp Ile Ile Leu Gly Ala Phe Ile Leu Leu Val Leu 195 200 205 Met Gly Ile Val Leu Ile Cys Val Trp Trp Gln Asn Gly Glu Trp Gln 210 215 220 Ala Gly Leu Trp Pro Leu Arg Thr Ser 225 230 <210> 37 <211> 198 <212> PRT <213> Homo sapiens <400> 37 Gly Leu Ala Asp Pro His Ser Leu Cys Tyr Asp Ile Thr Val Ile Pro 1, 5, 10, 15 Lys Phe Arg Pro Gly Pro Arg Trp Cys Ala Val Gln Gly Gln Val Asp 20, 25, 30 Glu Lys Thr Phe Leu His Tyr Asp Cys Gly Ser Lys Thr Val Thr Pro 35, 40, 45 Val Ser Pro Leu Gly Lys Lys Leu Asn Val Thr Thr Ala Trp Lys Ala 50, 55, 60 Gln Asn Pro Val Leu Arg Glu Val Val Asp Ile Leu Thr Glu Gin Leu 65 70 75 80 Leu Asp Ile Gin Leu Glu Asn Tyr He Pro Lys Glu Pro Leu Thr Leu 85 90 95 Gln Ala Arg Met Ser Cys Glu Gin Lys Ala Glu Gly His Gly Ser Gly 100 105 110 Ser Trp Gin Leu Ser Phe Asp Gly Gin He Phe Leu Leu Phe Asp Ser 115 120 125 Glu Asn Arg Met Trp Thr Thr Val His Pro Gly Ala Arg Lys Met Lys 130 135 140 Glu Lys Trp Glu Asn Asp Lys Asp Met Thr Met Ser Phe His Tyr He 145 150 155 160 Ser Met Gly Asp Cys Thr Gly Trp Leu Glu Asp Phe Leu Met Gly Met 165 170 175 Asp Ser Thr Leu Glu Pro Ser Ala Gly Ala Pro Pro Thr Met Ser Ser 180 185 190 Gly Thr Ala Gin Pro Arg 195 <210> 38 <211> 193 <212> PRT <213> Homo sapiens <400> 38 Arg Arg Asp Asp Pro His Ser Leu Cys Tyr Asp lie Thr Val lie Pro 1 5 10 15 Lys Phe Arg Pro Gly Pro Arg Trp Cys Ala Val Gin Gly Gin Val Asp 20 25 30 Glu Lys Thr Phe Leu His Tyr Asp Cys Gly Asn Lys Thr Val Thr Pro 35 40 45 Val Ser Pro Leu Gly Lys Lys Leu Asn Val Thr Met Ala Trp Lys Ala 50 55 60 Gln Asn Pro Val Leu Arg Glu Val Val Asp lie Leu Thr Glu Gin Leu 65 70 75 80 Leu Asp lie Gin Leu Glu Asn Tyr Thr Pro Lys Glu Pro Leu Thr Leu 85 90 95 Gln Ala Arg Met Ser Cys Glu Gin Lys Ala Glu Gly His Ser Ser Gly 100 105 110 Ser Trp Gin Phe Ser lie Asp Gly Gin Thr Phe Leu Leu Phe Asp Ser 115 120 125 Glu Lys Arg Met Trp Thr Thr Val His Pro Gly Ala Arg Lys Met Lys 130 135 140 Glu Lys Trp Glu Asn Asp Lys Asp Val Ala Met Ser Phe His Tyr lie 145 150 155 160 Ser Met Gly Asp Cys Ile Gly Trp Leu Glu Asp Phe Leu Met Gly Met 165 170 175 Asp Ser Thr Leu Glu Pro Ser Ala Gly Ala Pro Leu Ala Met Ser Ser 180 185 190 Gly <210> 39 <211> 124 <212> PRT <213> Homo sapiens <400> 39 Lys Leu Thr Arg Asp Ser Gln Ser Leu Cys Pro Tyr Asp Trp Ile Gly 1 5 10 15 Phe Gln Asn Lys Cys Tyr Tyr Phe Ser Lys Glu Glu Gly Asp Trp Asn 20 25 30 Ser Ser Lys Tyr Asn Cys Ser Thr Gln His Ala Asp Leu Thr Ile Ile 35 40 45 Asp Asn Ile Glu Glu Met Asn Phe Leu Arg Arg Tyr Lys Cys Ser Ser 50 55 60 Asp His Trp Ile Gly Leu Lys Met Ala Lys Asn Arg Thr Gly Gln Trp 65 70 75 80 Val Asp Gly Ala Thr Phe Thr Lys Ser Phe Gly Met Arg Gly Ser Glu 85 90 95 Gly Cys Ala Tyr Leu Ser Asp Asp Gly Ala Ala Thr Ala Arg Cys Tyr 100 105 110 Thr Glu Arg Lys Trp Ile Cys Arg Lys Arg Ile His 115 120 <210> 40 <211> 126 <212> PRT <213> Homo sapiens <400> 40 Trp Ser Lys His Ala Lys Pro Val Ala Cys Ser Gly Asp Trp Leu Gly 1 5 10 15 Val Arg Asp Lys Cys Phe Tyr Phe Ser Asp Asp Thr Arg Asn Trp Thr 20 25 30 Ala Ser Lys Ile Phe Cys Ser Leu Gln Lys Ala Glu Leu Ala Gln Ile 35 40 45 Asp Thr Gln Glu Asp Met Glu Phe Leu Lys Arg Tyr Ala Gly Thr Asp 50 55 60 Met His Trp Ile Gly Leu Ser Arg Lys Gln Gly Asp Ser Trp Lys Trp 65 70 75 80 Thr Asn Gly Thr Thr Phe Asn Gly Trp Phe Glu Ile Ile Gly Asn Gly 85 90 95 Ser Phe Ala Phe Leu Ser Ala Asp Gly Val His Ser Ser Arg Gly Phe 100 105 110 Ile Asp Ile Lys Trp Ile Cys Ser Lys Pro Lys Tyr Phe Leu 115 120 125 <210> 41 <211> 261 <212> PRT <213> Homo sapiens <400> 41 Met Phe Glu Ala Arg Leu Val Gln Gly Ser Ile Leu Lys Lys Val Leu 1 5 10 15 Glu Ala Leu Lys Asp Leu Ile Asn Glu Ala Cys Trp Asp Ile Ser Ser 20 25 30 Ser Gly Val Asn Leu Gln Ser Met Asp Ser Ser His Val Ser Leu Val 35 40 45 Gln Leu Thr Leu Arg Ser Glu Gly Phe Asp Thr Tyr Arg Cys Asp Arg 50 55 60 Asn Leu Ala Met Gly Val Asn Leu Thr Ser Met Ser Lys Ile Leu Lys 65 70 75 80 Cys Ala Gly Asn Glu Asp Ile Ile Thr Leu Arg Ala Glu Asp Asn Ala 85 90 95 Asp Thr Leu Ala Leu Val Phe Glu Ala Pro Asn Gln Glu Lys Val Ser 100 105 110 Asp Tyr Glu Met Lys Leu Met Asp Leu Asp Val Glu Gln Leu Gly Ile 115 120 125 Pro Glu Gln Glu Tyr Ser Cys Val Val Lys Met Pro Ser Gly Glu Phe 130 135 140 Ala Arg Ile Cys Arg Asp Leu Ser His Ile Gly Asp Ala Val Val Ile 145 150 155 160 Ser Cys Ala Lys Asp Gly Val Lys Phe Ser Ala Ser Gly Glu Leu Gly 165 170 175 Asn Gly Asn Ile Lys Leu Ser Gln Thr Ser Asn Val Asp Lys Glu Glu 180 185 190 Glu Ala Val Thr Ile Glu Met Asn Glu Pro Val Gln Leu Thr Phe Ala 195 200 205 Leu Arg Tyr Leu Asn Phe Phe Thr Lys Ala Thr Pro Leu Ser Ser Thr 210 215 220 Val Thr Leu Ser Met Ser Ala Asp Val Pro Leu Val Val Glu Tyr Lys 225 230 235 240 Ile Ala Asp Met Gly His Leu Lys Tyr Tyr Leu Ala Pro Lys Ile Glu 245 250 255 Asp Glu Glu Gly Ser 260 <210> 42 <211> 194 <212> PRT <213> Homo sapiens <400> 42 Gln Gly His Leu Val His Met Thr Val Val Ser Gly Ser Asn Val Thr 1 5 10 15 Leu Asn Ile Ser Glu Ser Leu Pro Glu Asn Tyr Lys Gin Leu Thr Trp 20 25 30 Phe Tyr Thr Phe Asp Gin Lys Ile Val Glu Trp Asp Ser Arg Lys Ser 35 40 45 Lys Tyr Phe Glu Ser Lys Phe Lys Gly Arg Val Arg Leu Asp Pro Gin 50 55 60 Ser Gly Ala Leu Tyr Ile Ser Lys Val Gin Lys Gin Asp Asn Ser Thr 65 70 75 80 Tyr Ile Met Arg Val Leu Lys Lys Thr Gly Asn Gin Gin Gin Trp Lys 85 90 95 Ile Lys Leu Gin Val Leu Asp Pro Val Pro Lys Pro Val Ile Lys Ile 100 105 110 Glu Lys Ile Glu Asp Met Asp Asp Asn Cys Tyr Leu Lys Leu Ser Cys 115 120 125 Val Ile Pro Gly Gin Ser Val Asn Tyr Thr Trp Tyr Gin Asp Gin Arg 130 135 140 Pro Phe Pro Lys Gin Leu Gin Asn Ser Val Leu Glu Thr Thr Leu Met 145 150 155 160 Pro His Asn Tyr Ser Arg Cys Tyr Thr Cys Gin Val Ser Asn Ser Val 165 170 175 Ser Ser Lys Asn Gly Thr Val Cys Leu Ser Pro Pro Cys Thr Leu Ala 180 185 190 Arg Ser

Claims

1. A method for preparing an NK cell population, comprising the following steps: (1) Prepare an NK cell population, IgG that can bind to NK cells via CD16 of NK cells, and a fusion protein. The fusion protein consists of region I, which can bind to NKp46, a surface protein of NK cells, and region II, which can bind to the Fc region of IgG, and a linker portion connecting region I and region II. Region I is the amino acid sequence from position 160 to position 404 of sequence number 2, and region II is the amino acid sequence from position 20 to position 144 of sequence number 2. (2) Adding antibodies to the NK cell population yields an NK cell population that binds to the antibodies. In the presence of the fusion protein, NK cells bind to region I of the fusion protein, and the antibodies bind to region II of the fusion protein. The fusion protein stabilizes the binding between NK cells and antibodies. in, The NK cell population is a population of NK cells containing CCR5-positive, CCR6-positive, and CXCR3-positive but CD3-negative cells. The cells that are CCR5-positive, CCR6-positive, and CXCR3-positive but CD3-negative Further, the expression of CD11a and CD11c was high, and this high expression was determined by comparison with the expression in a population of NK cells obtained from peripheral blood that had not undergone parenchymal culture. Further, the results showed that the integrin α1 was positive, the integrin α3 was positive, and the integrin β3 was negative.

2. The preparation method according to claim 1, wherein, IgG is an antibody drug used to treat cancer or infectious diseases.

3. A pharmaceutical composition comprising a population of NK cells that bind to an antibody drug via CD16 of NK cells, wherein the binding of the antibody drug to the NK cells is stabilized via a fusion protein. The fusion protein consists of region I, which can bind to NKp46, a surface protein of NK cells, and region II, which can bind to the Fc region of IgG, as well as a linker portion connecting region I and region II. Region I is the amino acid sequence from position 160 to position 404 of sequence number 2, and region II is the amino acid sequence from position 20 to position 144 of sequence number 2. NK cells are CCR5-positive, CCR6-positive, and CXCR3-positive cells that are CD3-negative. The cells that are CCR5-positive, CCR6-positive, and CXCR3-positive but CD3-negative Further, the expression of CD11a and CD11c was high, and this high expression was determined by comparison with the expression in a population of NK cells obtained from peripheral blood that had not undergone parenchymal culture. Further, the results showed that the integrin α1 was positive, the integrin α3 was positive, and the integrin β3 was negative.